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ABSTRACT 
Economics is a science that finds broad application in health care. By means of 
assessing benefits and costs associated with a health care program or the introduction of a 
new health technology, it represents a powerful tool in the decision-making process of 
allocating scarce resources in order to improve health outcomes. Acute Kidney Injury (AKI) 
is a frequent and severe complication affecting many hospitalized patients after cardiac 
surgery. As described in this work, AKI has a negative impact on short- and long-term 
clinical outcomes, as well as on health care costs. Prevention and early detection of the 
disease may help avoiding negative outcomes and AKI-associated costs. The present 
dissertation focuses on the evaluation of the NephroCheck® Test as a diagnostic tool for the 
early detection of AKI in a population of patients undergoing cardiac surgery. Specifically, 
this work assesses the ability of the NephroCheck® Test to predict the probability of 
developing AKI after cardiac surgery and evaluates its accuracy as a diagnostic test. 
 
 
SOMMARIO 
L’economia è una scienza che trova ampia applicazione nel settore della sanità. 
Valutando i benefici ed i costi associati ad un programma sanitario ovvero all’introduzione di 
una nuova tecnologia sanitaria, essa rappresenta un importante strumento all’interno del 
processo decisionale per l’allocazione di risorse scarse finalizzato al miglioramento degli 
outcome clinici. Il danno renale acuto (AKI, Acute Kidney Injury) è una complicanza 
frequente e grave, che affligge molti pazienti ospedalieri successivamente ad intervento 
cardio-chirurgico. Come descritto in questo lavoro, AKI esercita un impatto negativo sugli 
outcome clinici di breve e di lungo termine, così come sui costi del sistema sanitario. La 
prevenzione e l’individuazione precoce del danno possono aiutare ad evitare tali outcome 
negativi ed i costi associati ad AKI. Questa dissertazione è incentrata sulla valutazione del 
NephroCheck® Test quale strumento per la diagnosi precoce del danno renale acuto, in una 
popolazione di pazienti sottoposti ad intervento cardio-chirurgico. In particolare, il presente 
studio VALUTA l’abilità del NephroCheck® Test di predire la probabilità di sviluppare AKI 
successivamente ad un’operazione cardio-chirurgica e ne stima l’accuratezza quale test 
diagnostico. 
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INTRODUCTION 
The increasing cost of health and medical care services requires the evaluation of new 
therapies, interventions, devices, medical technologies and diagnostic instruments, in order to 
ensure that the limited resources are directed towards those programs that are expected to 
deliver the highest outcome. This assessment process covers multiple interrelated aspects. It is 
not limited to the benefits and costs associated to the introduction of a new health care 
program or technology, but it must include an evaluation of the clinical efficacy of the 
intervention and its feasibility in clinical practice, as well as considerations about longer-term 
impacts. It turns out that the evaluation of health care programs is a multidisciplinary process, 
in which different disciplines contribute and must be integrated together. Clinical issues are 
likely to have relevant economic consequences as well as organizational and social impacts 
that must be accounted for when it comes to evaluate an intervention in health care. 
Acute Kidney Injury (AKI) is an increasingly common and severe complication 
affecting hospitalized patients that implies damage to the kidney. It is particularly common 
following cardiac surgery and in intensive care unit (ICU), where incidence can reach 40% 
and 25%, respectively (De Smedt et al. 2012). It is associated with adverse clinical outcomes, 
including increased morbidity and in-hospital mortality, longer hospital stay, additional 
treatments needed. AKI has also a long-term impact on patient’s clinical outcomes, with 
increased mortality, possible progression to chronic kidney disease (CKD) and resulting 
negative economic effects (Mariscalco et al. 2011, and De Smedt et al. 2012). The annual cost 
of AKI-related inpatient health care in England has been estimated around £1,2 billion by 
Kerr et al. (2014).  
AKI happens fast and, unfortunately, there is still no specific treatment designed for it. 
Nevertheless, early detection of the injury may facilitate management and quicken 
identification and initiation of an effective therapy. However, current diagnostic methods – 
based on serum creatinine (SCr) as a marker of kidney function and on urine output – are 
confounded by many other factors and change slowly after the injury has already occurred. 
Consequently, this prevents early recognition of AKI cases and hampers timely interventions, 
a fact which might explain the extremely negative outcomes related to this disease. 
Based on the principle that timely AKI recognition may help dealing with the injury 
effectively, through careful monitoring of patient’s conditions and initiation of appropriate 
therapies, latest studies have focused on the search for more efficient diagnostic methods, 
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including AKI prediction scores and discovery and validation of other markers as possible 
alternatives to SCr. As a result, many urinary and serum proteins have been identified and 
investigated as possible early biomarkers (acronym for biological markers), which can help 
recognizing patients at risk of developing AKI. Two of these biomarkers, combined together, 
seem to have the best performance in terms of early detection of AKI risk (Kashani et al. 
2013): urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of 
metalloproteinases-2 (TIMP-2). The NephroCheck® Test (Astute Medical, San Diego, CA, 
USA) is an immunoassay that has been developed to measure the concentration of TIMP-2 
and IGFBP-7 in urine and to combine them together for the provision of a single numerical 
test result. 
The present dissertation has the purpose of evaluating the NephroCheck® Test as a 
diagnostic instrument to detect AKI early, in a population of patients undergoing cardiac 
surgery. A retrospective study has been conducted at the San Bortolo Hospital and the 
International Renal Research Institute of Vicenza (IRRIV), under the supervision of the 
Director of the Department of Nephrology, Dialysis, Transplantation and of the IRRIV, Prof. 
Claudio Ronco. A team of specialists and researchers, including physicians and biologists, has 
also been involved in order to conduct the study with a multidisciplinary approach. Deep 
knowledge of the clinical issues and aspects related to AKI as well as an insight into 
diagnostic procedures helped in the outline and development of the research project. Indeed, 
in order to evaluate the predictive ability of the NephroCheck® Test as a diagnostic device, a 
logistic regression model for the AKI prediction has been constructed. The scope was to build 
a model predicting the probability of developing AKI after cardiac surgery, based on a set of 
patient’s characteristics at admission, surgery procedures and therapies. Subsequently, the 
NephroCheck® Test results had to be added to the model, in order to evaluate any 
improvement in the predictive ability of the model attributable to the test. 
This dissertation is structured as follows. 
Chapter 1 provides a brief introduction on the economic evaluation of health care 
programs and explains why it has become an important component of a more comprehensive 
decision-making process concerning resource allocation among alternative projects. Tools and 
main issues to be addressed, as well as the main types of economic evaluation in health care 
are shortly described.  
The relevant problem is introduced in Chapter 2, from a slightly clinical point of view. 
Researchers and clinicians have struggled, over the past years, due to the lack of a widely 
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accepted definition and classification of AKI according to its severity; this problem has also 
hampered comparability of studies’ results. This chapter describes in details the latest 
definition and classification of AKI, adopted also in the course of this study. The issue of AKI 
diagnosis is also dealt with and the role of novel biomarkers is outlined. After introducing the 
relevant framework and the features that are deemed necessary for a successful biomarker, the 
latest studies investigating the performance of TIMP-2 and IGFBP-7 are briefly reviewed. 
This provides a scenario to understand the potential of the NephroCheck® Test as a new 
diagnostic instrument. 
Chapter 3 provides a theoretical framework for logistic regression model and receiver 
operating characteristic (ROC) curve analysis. ROC curves are, indeed, largely employed to 
evaluate the performance of classifiers and diagnostic devices that are meant to discriminate 
between diseased and non-diseased individuals. 
A brief review of the existent literature dealing with clinical outcomes following AKI 
and consequent economic burden is provided in Chapter 4. The impact of AKI is described 
into more details, based on the findings from most recent single-centre studies. It will be clear 
that the lack of a uniform definition and classification of AKI has hampered, so far, 
comparison among studies and has made it difficult to get clear-cut results in terms of impact 
on clinical outcomes and healthcare costs. Nevertheless, all the presented results point in the 
same direction, signalling that AKI has, indeed, a relevant impact on healthcare expenditure 
as well as it negatively affects clinical outcomes. From the review of the literature in this 
field, some important facts can be drawn about the relevance of AKI: AKI is an issue also in 
its milder cases, being always associated with increased health care costs and adverse clinical 
outcomes, and these negative effects are likely to prolong over a longer-term, beyond the 
hospitalization period.  
Finally, Chapter 5 illustrates the empirical results of a retrospective cohort study for 
evaluating the NephroCheck® Test as a diagnostic device. The objective of the study was to 
assess whether the NephroCheck® Test improves AKI prediction through a multiple logistic 
regression model, which accounts for other patients’ characteristics as well as surgical 
procedures and post-operative parameters. To do so, data from two cohorts of patients 
undergoing cardiac surgery during 2014 and 2015 in the San Bortolo Hospital of Vicenza 
were considered. For the 2015 cohort only, the NephroCheck® Test was available and 
employed. This chapter illustrates the steps for selecting the relevant variables to be included 
in the base model and analyses the performance of the model before and after including the 
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results of the test. Finally, by means of comparing the performance of the models in 
discriminating between AKI and non-AKI individuals, it can be evaluated if the 
NephroCheck® Test is a powerful and effective diagnostic tool.  
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1 ECONOMIC ANALYSIS 
1.1 HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT 
Economics is the study of resource allocation among alternative uses when resources 
are scarce. It is the science that analyses how individuals and societies choose to allocate 
scarce resources, among competing alternative uses, to satisfy their unlimited wants and 
needs, and to redistribute the products of this allocation. In particular, economic evaluation 
can be defined as a tool for assessing the benefits and the costs of competing uses of scarce 
resources. To pursue this aim, economic evaluation embeds two aspects. Firstly, both 
resources to be invested (inputs or costs) and the products (outputs or benefits) of a particular 
activity are analysed. Secondly, the problem of scarcity of resources must be addressed by 
considering how inputs might be allocated among alternative uses. 
Economics has found broad application in many fields, including health care. Health 
economics (HE) is the discipline that, employing economic concepts and tools, studies how to 
allocate scarce resources to improve health (see Kobelt 2013). In the context of health care, 
economic evaluation is “a comparative analysis of alternative courses of actions in terms of 
both their costs and consequences” (Drummond et al. 2005). This encompasses decisions on 
resource allocation to the healthcare system within the economy as well as to different and 
competing activities within the healthcare system itself. 
Health expenditure measures the final consumption of health goods and services (i.e. 
current health expenditure). This includes spending by both public and private sources on 
medical services and goods, public health and prevention programmes and administration, 
while spending on capital formation (investments) are excluded (see OECD 2015). The figure 
below shows that health expenditure as a percentage of GDP was on average 8.9% in the 
OECD countries during 2013. 
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As far as the trend in health expenditure is concerned, most of the second half of the 
20th century and the beginning of the 2000s were characterized by a steady increase in health 
spending as a share of GDP. Things changed during the financial crisis around 2008 when, 
after an initial increase due to the sharp fall in GDP, health expenditure on GDP decreased 
gradually in many OECD countries until they reached a stabilisation, following economic 
growth (Figure 1.2). 
 
The great variation in the amount of money that countries spend on health is related to 
Note: Excluding investments unless otherwise stated.  
1. Data refers to 2012 
2. Including investments 
Source: OECD. 	
Figure 1.1 Health expenditure as a share of GDP, 2013 (or nearest year).	
Figure 1.2 Trends in health expenditure.	
OECD countries: blue line. Italy: red line. 
Source: OECD 	
Total	health	expenditure,	%	of	GDP	 Public	health	expenditure,	%	of	GDP	 Expenditure	on	pharmaceuticals,	%	GDP	
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country-specific budget priorities but also to the determinants of health expenditure, which 
influence the choice of countries and may stimulate or limit the investments in health. One of 
the primary drivers of health expenditure is certainly the demographic structure of a 
population. In particular, the phenomenon of an ageing population, along with growing life 
expectancy and low fertility rates, characterizes most developed countries and has contributed 
to the increase in health care spending (see Dybczak and Przywara 2010). Indeed, although 
consumption of health services depends on health status, the elderly tend to use health care 
more than the younger cohorts. However, Oliveira Martins and de la Maisonneuve (2006) 
argue that the link between demographic factors and health expenditure may be weaker than 
one expects, with other non-demographic factors playing a relevant role. Firstly, income 
growth positively influences both private and public spending on health care, which are led by 
a greater awareness on health status and availability of new therapies. Nevertheless, the 
relationship between GDP and spending on health care depends substantially on income 
elasticity of demand for health services, whose value is still the central issue of a large debate 
(Dybczak and Przywara 2010). Also technological progress is viewed by many economists as 
one of the main drivers of health care costs, as it is “the most important supply factor 
affecting the entire process of development, production, delivery and financing of health care” 
(Dybczak and Przywara 2010, 6). 
Keeping the costs of health care under control has become a core concern particularly in 
those countries where health is mainly publicly funded, through taxes and/or social insurance. 
Across all OECD countries, health care is financed through a mix of public and private funds 
(in the form of household’s payments and/or private health insurance), and government 
spending usually represents the main source of funds (OECD 2015). 
In this context, Health Technology Assessment (HTA) is the field of scientific research 
that informs policy and clinical decision-making on the introduction and use of health 
technologies. These include pharmaceuticals, devices, diagnostics, procedures and other 
clinical, public health and organizational interventions. Kobelt (2013, 1) defines HTA as a 
“multidisciplinary process that summarises information about the medical, social, economic 
and ethical issues related to the use of a health technology throughout its life span in a 
transparent, systematic, unbiased and robust manner”. HTA thus examines short- and long-
term impact of new health technology and provides policy makers with necessary knowledge 
about policy alternatives, supporting an informed decision (Banta 2009). 
Technology assessment related to the healthcare system developed remarkably since the 
	8	
last decades of the 20th century and was especially concerned with the safety, cost-
effectiveness and efficacy aspects of technology (see Banta 2009). Later on, also the social 
and ethical issues became important, although cost-effectiveness remained a prominent focus 
that was exacerbated by the financial crisis of the late 2000s. Economic evaluation is part of 
HTA and it is a component of a more comprehensive assessment and decision process, where 
different disciplines must be integrated together with the purpose of advising in the allocation 
of scarce resources between available alternatives. 
The patients –consumers of the new services and technologies – fuel the demand for 
HTA as they expect more and better information about alternative methods of treatment 
(Jennet 1992). The public's participation not only influences the priorities of research and 
provision, but it also helps defining broader outcomes for the assessment process itself, such 
as quality of life both during and after treatment. 
Economic evaluation is often based on the relative efficacy observed in the controlled 
environment of a clinical trial. This may represent a limit of the appraisal process that would 
rather need to assess the effectiveness, hence cost-effectiveness, of the treatment in the 
uncontrolled environment of normal clinical practice (Kobelt 2013, and Drummond et al. 
2005). However, the existing techniques for economic evaluation also try to overwhelm the 
limits related to the features of a controlled clinical trial and attempt to deliver general results 
with a broader application. 
 
1.2 METHODS FOR ECONOMIC EVALUATION 
There are several techniques for economic evaluation, all of them using similar 
approaches to estimate costs but different methods for measuring consequences, and they are 
“always comparative and applied to explicit alternatives” (Kobelt 2013, 12). The guiding 
principle consists in choosing the alternative that maximizes health outcome given a resource 
constraint. If two strategies deliver the same outcome, the one that costs less is always 
preferred. Although a technology that delivers a better outcome is normally preferable to 
existing ones, an outcome improvement often comes at higher costs. Thus, an incremental 
cost-effectiveness ratio (ICER) must be computed to compare alternative strategies. An ICER 
is the extra investment required for an additional health benefit and it is calculated as the ratio 
between the difference in cost and the difference in effect of two alternative interventions, A 
and B: 
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ICER = 𝐶! − 𝐶!𝐸! − 𝐸! 
The ICER can be employed as a decision tool by defining a willingness-to-pay (WTP) 
threshold. If the incremental cost per unit of health benefit is below such threshold, then the 
(more costly) intervention should be adopted (Kobelt 2013). 
The perspective assumed in a HE analysis (e.g. society, patient, healthcare provider, 
third-party payer) determines the scope and the extent of costs and benefits that are assessed. 
From a global standpoint, the usual “reference point” is the societal perspective and this is 
usually the most comprehensive of all approaches, as all relevant costs are accounted for over 
the specified time horizon, regardless of who incurs them. Adopting a societal perspective 
also avoids foregoing important benefits that would not be captured by a narrow, budget-
specific viewpoint and that could lead to a sub-optimal resource allocation. However, other 
perspectives are often vital as they inform key decision makers and stakeholders about the 
impact of health interventions from their vantage point. 
Regardless of perspective that is chosen, a transparent analysis must also precisely 
specify the time period considered in the study and the time span of interest in order to ensure 
that the relevant costs and outcomes attributable to the study’s perspective and scope are 
accounted for and assigned (Jegers et al. 2002). 
When two alternative strategies with the same goal are being evaluated, there is the 
possibility that some costs are the same for the alternatives, thus having no impact on the 
results of the evaluation process. Identification of the relevant resources consumed to be 
included in the analysis is a necessary step for cost estimation. Indeed, costs are computed by 
multiplying the units of resource used by their unit price, which should represent their 
opportunity cost – the value of forgone benefit that could be obtained from a resource in its 
next best alternative use. Typical costs associated to resource use can be classified as follows: 
• direct medical costs: costs to the healthcare system (e.g. hospitalization, visits, drugs, 
tests and procedures, medical devices, nursing care); 
• direct non-medical costs: expenses associated to the care of a patient, such as, 
transportation, related services, devices etc. Care provided by family members, also 
known as informal care, is included either in this category or in the following one; 
• indirect costs: productivity losses that represent a cost to the society and are related to 
time spent off of work, on behalf of the patient (sick days, impaired productivity at 
work, early retirement or premature death). 
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In order to adjust for different timing at which resource use takes place and benefits 
accrue, another important aspect of HE assessment is discounting, or the determination of the 
present value of future costs and benefits. Although no consensus on the most appropriate 
discount rate exists, there are two main options for choosing the discount rate. The former is 
the real interest rate, which is the foregone return rate on alternative investments for the 
society. The latter is the rate that reflects social temporal preferences. In practice, however, it 
is difficult to select an appropriate discount rate; it is rather preferred to present costs in 
undiscounted form and perform a sensitivity analysis, considering discount rates of 0%, 3% 
and 5% (Drummond et al. 2005). Indeed, an inherent component that underlies almost all 
economic analyses is the concept uncertainty, due to the fact that several variables (e.g. 
discount rate, precise costs, mortality and morbidity rates, etc.) are often unknown. 
Uncertainty is related to many factors, including lack of precision in variables estimates, the 
absence of data and the reliance upon lower levels of scientific evidence, and also to inherent 
technical and technological limits of applied levels of scientific evidence (Heyland et al. 
1999). To attenuate uncertainty, HE analyses employ comprehensive and sophisticated 
sensitivity analysis to illustrate how changes in key underlying variables used in studies and 
models influence changes in cost, outcomes and cost effectiveness. 
In the following paragraphs, different types of economic evaluation will be described. 
As already noted, what distinguishes the different techniques is how outcomes are treated. In 
particular, a medical issue lies behind the economic analysis: whether the evaluation process 
provides support in choosing between alternative treatments for the same disease or informs 
about what interventions for different diseases should be prioritized. 
 
1.2.1 COST-BENEFIT ANALYSIS 
In a cost-benefit analysis (CBA), consequences of programs are defined in monetary 
units, so that the comparison between incremental costs and incremental benefits of the health 
program is straightforward. In particular, the discounted stream of future benefits (in 
monetary terms) is compared with the stream of costs, giving rise to the net benefit/cost of the 
policy. If the difference between the stream of benefits and costs is positive, there is a net 
benefit and the intervention is actually acceptable from the viewpoint of the society. The 
ultimate objective of the CBA is the efficient allocation of resources not only within the 
health sector, by means of allowing a comparison between alternative investments in different 
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sectors of the economy (Kobelt 2013). Indeed, it evaluates the health program on the basis of 
all the outcomes, not just in terms of health, thus representing a complete evaluation method. 
In a CBA, costs are measured as opportunity costs, while benefits are expressed as the 
maximum willingness to pay (WTP) for the outcome of the program. WTP is a measurement 
technique to evaluate, in monetary terms, the health gains and other kinds of benefits arising 
from a program. In particular, three main categories of benefits can arise from a program: 
future costs that will be avoided, health gains and improvements (intangible benefits), 
productivity gains due to better health conditions. WTP usually accounts only for part of these 
benefits, in particular the health gains. 
As far as the valuation of benefits in monetary terms is concerned, several approaches 
have been proposed (see Drummond et al. 2005). 
The human capital approach is based on the idea that the time spent by a person in 
good health is “convertible” in terms of higher productivity on the labour market. The health 
outcome is thus evaluated on the basis of the market salaries, in relation to the time spent by a 
person in good health. However, this approach has some important limitations. Although the 
salary can be considered an approximation of the marginal productivity of the worker, a lot of 
market imperfections are likely to influence the analysis, such as inequalities on the labour 
market. Moreover, if the analysis assumes the perspective of the society, then the outcome is 
the “time gained in good health”, which is not fully convertible in terms of salary. This is, for 
example, the case of a housewife whose occupation is not “traded” on the labour market, but 
it is nevertheless valuable to her family and, thus, to the society. Lastly, another criticism 
concerns the importance of accounting for the collective WTP for the program, which is 
likely to put this approach in contrast with the paretian principles of Welfare Economy. 
An alternative approach (known as the revealed preferences) considers the trade-off 
between risk and salary, in order to analyse the relationship between the health risks 
associated with an occupation and the salary that the individual requires to accept that job. 
This is consistent with the Welfare Economy Principles, because it is based on the 
individuals’ preferences towards the increase/reduction of the salary related to a health risk. 
The third (and most widely used) method is that of contingent valuation: individuals 
participate surveys and are asked to imagine hypothetical (contingent) scenarios and to reveal 
their maximum WTP for the realization of a program – with the consequent benefits that it 
delivers. The main limit to the application of this method derives from the difficulty in 
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estimating, in monetary terms, the WTP of the individuals, through the questions that they are 
asked to answer. 
According to Drummond et al. (2005), CBA can be considered the most powerful 
valuation approach since it addresses the issue of allocative efficiency. However, the main 
drawback consists in the difficulties arising when trying to value (in monetary terms) the 
intangible benefits of a health program. 
 
1.2.2 COST-EFFECTIVENESS ANALYSIS 
The CEA (cost-effectiveness analysis) is a valuation method of health programs, which 
takes into account both the costs and the consequences of a policy intervention. The 
incremental cost of a program is, indeed, compared to the incremental gains in terms of 
health. Health consequences are measured in physical units correlated with the policy 
objective and are usually expressed in terms of reduced mortality and morbidity or life years 
gained. The economic evaluation should, thus, account for the final outcome of a policy over 
the long term; however, this is often not available or requires a long time (and consequently a 
lot of resources) to be measured. An alternative procedure consists in measuring the 
intermediate outcomes and finding a link with the final ones. 
The crucial decision tool is the ICER that is used to compare interrelated interventions, 
in the sense that they usually address the same issue and deliver similar outcome (Tan-Torres 
Edejer et al. 2003). Alternatively, the estimated cost-effectiveness of the new project is 
compared with a fixed price cut-off point representing the assumed social WTP for an 
additional unit of health, expressed as one of the previously described measures. Figure 1.3 
below represents the cost-effectiveness plane that provides a framework for the policy 
maker’s choice. The plane is divided into four quadrants, where effectiveness lies on the 
abscissa and costs on the ordinate. Apart from situations with a clearly dominant intervention 
compared to alternatives – less effective and more costly or more effective and less costly, 
represented in the fourth and second quadrants, respectively– there is usually the need for a 
threshold value. According to this threshold, represented by the dotted line, the decision 
maker decides whether the additional cost is justified by the additional benefit obtained. 
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A crucial issue in CEA is the valuation of policy effectiveness. It is mainly a matter of 
medical evidence, which raises the problems of quality of the data and relevance of results. 
Indeed, the design of a clinical study at the base of an economic analysis influences these two 
aspects (see Drummond et al. 2005). The endpoint should be to evaluate the effectiveness of a 
program – i.e. the real world outcome – not its efficacy – i.e. its theoretical outcome, in a 
controlled environment (Kobelt 2013). However, some clinical trials are designed in such a 
way that results are delivered more in terms of efficacy than proper effectiveness and, 
unfortunately, data on effectiveness may not be available. 
Another aspect to be considered in a CEA is the comprehensiveness, according to which 
clinical data should be representative of the data in the existing literature. A selective 
collection of clinical data may lead, indeed, to a more (or less) favourable economic 
evaluation. 
 
1.2.3 COST-UTILITY ANALYSIS 
This type of evaluation focuses on the quality of the policy outcome, in terms of health 
gains or diseases avoided due to the application of a health program. The incremental cost of 
a policy is compared to the health improvement attributable to the policy itself, measured in 
quality-adjusted life years (QALYs); results are expressed in terms of cost per QALYs 
gained. Other possible (but by far less used) measures of the outcome are disability-adjusted 
life years (DALYs) and healthy year equivalents (HYEs). These are all measures of health 
Source: Hounton and Newlands (2012) 
Figure 1.3 Cost-effectiveness plane. 	
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over a medium/long term, which incorporate the impact of interventions on years of life lost 
due to premature mortality and years of life spent with a disease, weighted by the severity of 
that outcome. 
It may appear similar to CEA, but there is a key difference concerning the measurement 
of the results. In a CUA (cost-utility analysis), the results may be composite and more 
complex with respect to the individual outcomes measured in a CEA, allowing the 
comparison of very different health programs (Kobelt 2013). QALYs is a measure of the 
outcome that incorporates two aspects: on the one side, the increase in life years (mortality), 
on the other side, the improvement in the quality of life (morbidity). QALYs is computed by 
weighting a time quantity, expressed by the increase in life years, by a quality adjustment 
measure representing the relative preference that individuals or society place on different 
health states (i.e. utility). The final long-term outcome is, thus, necessary to conduct a CUA 
because this must be converted into QALYs, which is not possible for intermediate outcomes 
(Drummond et al. 2005). 
The crucial aspect of a CUA is to assess the utility valuation of health states, on behalf 
of the individuals. This means that a scale of preferences (ranking) towards different health 
outcomes must be defined, where a utility of one usually refers to full health and zero 
represents death. Two methods are commonly applied to define utilities associated to different 
health states (see Drummond et al. 2005, and Kobelt 2013). 
The first one consists in interviewing patients directly and collecting their subjective 
evaluations. Individuals are asked to rate different scenarios associated to their health and 
treatment received, usually through standard gambles or time trade-offs. This approach is, 
however, quite time-consuming and requires trained interviewers. 
The other method relies on preference-based generic quality-of-life questionnaires, the 
most widespread of which is the EuroQol Group’s EQ-5D. In this case, health states are 
associated to a predefined set of weights that allow calculating QALYs directly. For this 
purpose, health is characterized by five dimensions – mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression – each one measured on three levels of severity – 
coded as 1 (no problems), 2 (some problems), 3 (severe problems). A framework of 243 
theoretically possible health states (plus death and unconsciousness) can be defined, on the 
basis of an individual’s combination of attributes. 
Although it has many similarities with CEA, CUA might be a preferable method when 
the program needs to be evaluated both in terms of quantity and quality of life affected. 
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Moreover, it is more appropriate when the policy maker must choose among alternative 
programs – in other words, in case of resource allocation – because QALYs is a more generic 
measure of health outcome. 
 
1.3 DECISION ANALYTIC MODELS 
The golden rule for HE is to use clinical trial data in order to extrapolate values for 
costs and consequences. However, this is not always possible and trial data might not reflect 
what would happen in real clinical practice, limiting the generalizability of results. An 
alternative approach is to extrapolate from existing data to different population groups, longer 
time frames, or disease endpoints (Mandelblatt et al. 1997). Models are also employed in 
conducting sensitivity analyses on the parameters included. There are two most commonly 
used types of model structure: decision tree models and Markov models. Both consider the 
consequences of clinical actions under uncertainty and represent the possible evolution of 
events, accounting for probability that a subsequent health state occurs and a final outcome is 
obtained over a limited time frame. 
Decision tree models, in particular, represent events occurring either by chance or 
decisions over time. Each path in a decision tree depicts one possible sequence of events, 
associated with a probability and a final outcome (Mandelblatt et al. 1997). 
Recurring events are better represented through state-transition models, such as Markov 
models. Markov models are useful to describe disease outcomes and effects of interventions, 
because patients can be classified into mutually exclusive “Markov states” and move to a 
different state as the disease progresses or the intervention succeeds. Transitions occur within 
a specified time frame, called “Markov cycle”, and a whole model is made of different cycles 
until a final outcome is reached. These decision analytic models are particularly important in 
settings were risk of disease and disease progression may continuously change over time (see 
Kobelt 2013) and transition probabilities depend on the current state. 
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2 ACUTE KIDNEY INJURY AND BIOMARKERS FOR AN 
EARLY DIAGNOSIS 
2.1 THE KIDNEY 
The kidneys are two bean-shaped organs, each about the size of a fist. They are located 
against the back muscles in the upper abdominal cavity, one on each side of the spine. Each 
kidney is made up of about a million nephrons composed by a filter, the glomerulus, and a 
tubule; nephrons can be considered the filtering units allowing the kidney perform its 
functions. Indeed, the kidneys play a dominant role in regulating the composition and volume 
of the extracellular fluid by means of filtering about 200 litres of blood to produce about 2 
litres of urine, composed of wastes and extra fluid. In particular, they prevent the build-up of 
wastes and extra fluid in the body, they keep levels of chemicals (i.e. electrolytes) stable, they 
produce hormones that help regulate blood pressure, make red blood cells, produce vitamin D 
which is necessary for bones health.   
The filtration capacity of the kidneys can be measured by the Glomerular Filtration Rate 
(GFR), which estimates how much blood passes through the glomeruli each minute. In 
clinical practice, GFR is estimated using a biomarker, the serum creatinine (SCr) that is a 
waste molecule generated from muscle metabolism and mostly filtered out by the kidneys. 
Therefore, it is considered a fairly reliable indicator of kidney function. When the filtration 
capacity is reduced, the kidneys are no longer able to remove all the waste products. This 
means that the patient has a kidney or renal disease. In this setting, the GFR is important to 
define the grade and severity of the disease. Several kidney diseases, indeed, affect the 
filtering units of the nephrons compromising their capability to remove wastes and fluids. 
Kidney disease is classified as acute or chronic, and these conditions may lead to what 
is called end-stage renal disease (ESRD). 
Chronic Kidney Disease (CKD) is a slow, progressive and irreversible loss of kidney 
function (number of working nephrons) over a long period of time (months or years). Levin 
and Stevens (2014, p.52) define it as “abnormalities of kidney structure or function, present 
for more than 3 months, with implications for health”. CKD is classified according to cause, 
GFR category and albuminuria category. Based on GFR, the progression and stages of CKD 
can be defined as indicated in the following table. 
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Table 2.1 GFR categories in CKD 
Stage GFR (ML/MIN/1.73m2) Description 
G1 ≥90 Normal or high 
G2 60-89 Mildly decreased 
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased 
G5 <15 Kidney failure 
CKD: chronic kidney disease, GFR: glomerular filtration rate 
Source: Levin and Stevens (2014) 
 
Stage 5 is ESRD, which needs to be treated either through kidney transplantation or with 
dialysis. 
Conversely, Acute Kidney Injury (AKI) is a syndrome that results in a sudden decrease 
in renal function or kidney damage. AKI may lead to CKD or even kidney failure requiring 
dialysis. AKI is treated in a more detailed way in the following paragraphs. 
 
2.2 DEFINITION AND CLASSIFICATION OF AKI 
AKI is a common complication among hospitalized patients that affects kidney 
structure and function and it is associated with adverse clinical outcomes (KDIGO 2012 ch. 
2.1). As reported by Mariscalco et al. (2011), in cardiac surgery AKI occurs up to 40% of 
patients, while in intensive care unit (ICU) one out of four patients is affected by AKI (see De 
Smedt et al., 2012). AKI is associated with increased morbidity, longer hospital stay, 
increased mortality (approximately 50% among ICU patients), the need for renal replacement 
therapy (RRT) and, consequently, increases in healthcare costs (Mariscalco et al. 2011, and 
De Smedt et al. 2012). Negative outcomes correlated with AKI may be improved in case of a 
timely detection of AKI and the initiation of an appropriate therapy, as well as the 
identification of the underlying causes, the monitoring of progression and responses to 
interventions (Shaw, Chalfin and Kleintjens 2011). However, in the past, the lack of 
consensus in AKI definition and classification did not allow to estimate the right incidence 
and to compare study results. Due to the relevance of this disease, awareness of AKI has risen 
and efforts have been made in order to formulate a commonly accepted definition of AKI. 
GFR is still considered the most useful index of kidney function; nevertheless, changes in SCr 
	 19	
and urine output (UO) are used as surrogates of changes in GFR in order to define criteria for 
diagnosis and staging of AKI (see KDIGO 2012, ch. 2.1).  
In 2002, the first definition and classification of AKI stages was created in Vicenza 
during a 2-days conference by the Acute Dialysis Quality Initiative (ADQI): the RIFLE 
criteria (an acronym for Risk, Injury, Failure, Loss, End-stage kidney disease) were born. 
This classification is based on criteria for SCr and UO, with a patient that can fulfil either of 
the two criteria or both and is classified according to the one criterion leading to the worst 
classification (KDIGO 2012, ch. 2.1). Three classes of AKI severity (risk, injury and failure) 
and two outcome classes (loss of kidney function and end-stage renal disease) are defined. 
In 2007, a modified version of this classification was developed in order to increase 
specificity and sensitivity of AKI diagnosis: the AKIN (Acute Kidney Injury Network) 
classification. It distinguishes three AKI stages and does not consider the two outcome 
classes; it is based on criteria for SCr and UO but not on GFR changes. The figure below 
shows and compares these two classification criteria. 
Cr: creatinine, GFR: Glomerular filtration rate, ARF: acute renal failure. 
Source: Cruz, Ricci and Ronco (2009), (adapted from Bellomo et al. 2004 and Mehta et al. 2007) 
Figure 2.1. RIFLE and AKIN classifications for acute kidney injury.	
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In 2012, the Kidney Disease Improving Global Outcomes (KDIGO) released their 
clinical practice guidelines for AKI, which build off of the RIFLE criteria and the AKIN 
criteria1. AKI is defined as any of the following conditions (without grading): 
• increase in SCr by ≥0.3 mg/dl (≥26.5 lmol/l) within 48 hours; or 
• increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred 
within the prior 7 days; or 
• urine volume <0.5 ml/kg/h for 6 hours. 
AKI is then staged for severity according to the criteria in the following table. 
 
Table 2.2 Staging of AKI 
Stage Serum creatinine Urine Output 
1 1.5-1.9 times baseline OR  ≥0.3 mg/dl 
(≥26.5 µmol/l) increase 
<0.5 ml/kg/h for 6-12 
hours 
2 2.0-2.9 times baseline <0.5 ml/kg/h for ≥12 hours 
3 3.0 times baseline OR increase in serum creatinine 
to ≥4.0 mg/dl (≥353.6 µmol/l) OR initiation of 
renal replacement therapy OR, in patients <18 
years, eGFR ˂ 35 ml/min per 1,73 m2  
0.3 ml/kg/h for ≥24 hours 
OR Anuria for ≥12 hours 
AKI: acute kidney injury 
Source: Adapted from KDIGO, ch. 2.1 (2012) 
The SCr is still the most widely used marker for quantification of renal function: it is 
easily recorded as part of routine analysis and it has a low cost. However, there are some 
relevant drawbacks concerning this approach. First of all, SCr levels are influenced by many 
non-renal factors (sex, age, race, muscle mass, diet and by certain drugs and clinical 
conditions) and an increase in its level normally occurs when half of kidney function is 
already lost, thus with substantial time delay with respect to kidney injury. Moreover, it does 
not adequately account for structural renal tubular injury, which may be extensive in the 
setting of AKI (Shaw, Chalfin and Kleintjens, 2011). Finally, difficulties arise in case of 
patients with renal dysfunction whose urine output is scarce. 
																																																								
1 See Acute Kidney Injury Work Group. Kidney Disease: Improving Global Outcomes (KDIGO) - Clinical 
Practice Guideline for Acute Kidney Injury. (2012) Kidney International Supplements, 2, 1-138. 
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All these issues related to the use of SCr as a marker for kidney function have raised the 
need of more efficient methods for AKI diagnosis, which has led to the discovery of other 
markers as possible alternatives. 
 
2.3 BIOMARKERS FOR EARLY DETECTION OF ACUTE KIDNEY 
INJURY 
Several studies have been conducted with the aim of identifying urinary and serum 
proteins as early biomarkers (acronym for biological markers) that can help in the early 
detection of kidney damage and possibly discern AKI subtypes. In particular, during the last 
years, efforts have been made in order to find and validate novel biomarkers for AKI, 
produced by genes as soon as few hours after the injury has occurred.  
Various proteins and biochemical markers have emerged as possible and promising 
candidates for a timely diagnosis of AKI; however, few of them have reached an “acceptable 
level of suitability or precision” (Wetz et al 2015, p 1). These biomarkers include, among 
others, kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), 
interleukin-18 (IL-18), Cystatine-C (CysC), N-acetyl-glucosaminidase (NAG) and fatty acid-
binding protein (FABP). The most important features of a good biomarker are defined in the 
KDIGO Clinical Practice Guideline (2012, ch. 2.1), by Tsigou et al. (2012, 1-2) and by Zhou 
et al. (2006) as follows: 
a. to diagnose renal dysfunction early; 
b. to allow a discrimination between pre-renal, intrinsic and post-renal causes; 
c. to provide information about the primary location of the injury (e.g. renal tubules, 
interstitium, vasculature); 
d. to provide a specificity for kidney injury in the presence of coexistent injury 
affecting other organs; 
e. to discern AKI from other forms of renal disease; 
f. to classify AKI according to severity; 
g. to monitor the progression and the response to therapy; 
h. to be cost-effective compared to current practice; 
i. to be analysed through relatively non-invasive and easy to perform tests; 
j. to have high degree of sensitivity. 
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New biomarkers may also help to detect patients with a subclinical risk of developing 
kidney injury; in other words, those cases in which, even in the absence of a renal 
dysfunction, a tubular damage to the kidney exists (see Zhou et al. 2006, and Haase, Kellum 
and Ronco 2012). The expression “subclinical” AKI is used with reference to this condition 
(see Haase, Kellum and Ronco, 2012, 1-2), such that AKI is not “clinically manifest” in the 
form of a decreased GFR and increased SCr, yet a structural damage to the kidney has 
happened and this fact exposes the patient to a higher risk of renal function loss in the future. 
For this reason, subclinical AKI should be in fact considered AKI. The role of new tubular 
damage biomarkers would be that of detecting a structural damage, when creatinine shows no 
evidence of renal dysfunction.   
A rule that defines how the biomarker is to be employed as a clinical diagnostic 
instrument must be specified. This means that a cut-off value distinguishing normal from 
abnormal levels of the biomarker needs to be identified, such that for every value of the 
marker that is higher than this cut-off there is a high risk for the patient to develop AKI.  
The performance of a biomarker at a variety of cut-off values can be graphically 
displayed through a receiver operating characteristic (ROC) curve. ROC curves are often used 
to graph the accuracy of diagnostic instruments along the scale of possible values, showing 
the trade-off between sensitivity and specificity for each value2. This allows selecting the best 
cut-off level, the value of the diagnostic test (the biomarker, in this case) that maximizes the 
difference between the so-called “true positives” and “false positives” (see D’Arrigo et al. 
2011). The area under ROC curve (AUC) evaluates, then, the overall quality (predictive 
ability) of the diagnostic instrument and a perfect biomarker should have an AUC of one 
(Zhou et al. 2006). Individual biomarkers usually have an AUC inferior to 1, but combining 
them with other biomarkers and/or other clinical information can increase the AUC of the 
whole diagnostic panel to approximate the desired value of 1 (see Figure 2.2). 
 							
																																																								2	See	the	following	chapter	for	more	details	on	ROC	curve	analysis.	
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2.4 THE NEPHROCHECK® TEST 
Among all the biomarkers that clinical studies are trying to evaluate and validate, two of 
them, combined together, are outperforming the others according to the latest studies (see 
Kashani et al. 2013): urine insulin-like growth factor-binding protein 7 (IGFBP7) and tissue 
inhibitor of metalloproteinases-2 (TIMP-2). They are soluble proteins, expressed in kidney 
and other tissues, and are thought to be involved in G1 cell-cycle arrest during the earliest 
phases of injury. Thus, both TIMP-2 and IGFBP7 are markers of cellular stress in the early 
phase of tubular cell injury caused by a wide variety of insult (see Wetz et al. 2015, and 
Ronco 2014). 
Example of how an area under the receiver-operating characteristic 
curve (AUC) may improve by means of combining a biomarker 
with other clinical information. 
Source: Zhou et al. (2006) 
Figure 2.2  
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Kashani et al. (2013) conducted a multi-centre observational study in North America 
and Europe, enrolling 744 critically ill patients at risk of developing AKI, where IGFBP7 and 
TIMP-2 were identified, for the first time, as the top-performing biomarkers among a set of 
existing novel biomarkers. The assessment of the biomarkers’ performance was primarily 
based on the value of the receiver operating AUC, which was 0.77 and 0.75 for IGFBP7 and 
TIMP-2, respectively, “for the identification of risk of developing AKI (RIFLE-I/F) within 12 
to 36 hours” (Kashani et al. 2013, 4). In particular, IGFBP7 and TIMP-2 seemed to have 
additive predictive value when used together. 
Consequently, in the further validation phase of the investigation, the so-called Sapphire 
study, the multiplication [TIMP-2]×[IGFBP7] of the two markers was evaluated: the AUC of 
this combination was 0.80, again, for the development of moderate to severe AKI (stage 2 to 
3) within 12 hours from sample collection. A primary clinical cut-off value of 0.3 was also 
derived, within the Sapphire study, as having a high sensitivity for predicting the development 
of moderate to severe AKI in the following 12 hours (see Ronco 2014). Figure 2.3 shows 
IGFBP7: insulin-like growth factor-binding protein 7, IL-18: interleukin-18, KIM-1: kidney 
injury molecule-1, L-FABP: liver-type fatty acid-binding protein, NGAL: neutrophil 
gelatinase-associated lipocalin, pi-GST: glutathione S-transferase Pi, TIMP-2: tissue 
inhibitor of metalloproteinases-2. 
Source: Kashani et al. (2013). 
Figure 2.3 Area under the receiver-operating characteristic curve (AUC) for 
TIMP-2 and IGFBP7, as compared to other existing biomarkers of AKI. 
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clearly how the two biomarkers (combined together but also alone) outperform other existing 
markers. 
For the purpose of this study, the NephroCheck® Test (Astute Medical, San Diego, CA, 
USA), which was developed by Astute Medical and employed in the Sapphire validation 
study, was used. The NephroCheck® Test is an immunoassay measuring the concentration of 
TIMP-2 and IGFBP-7 in urine and combining them together to provide “a single numerical 
test result” in a range between 0.04 and 10.0. The detection process takes place through the 
insertment of the NephroCheck® Test cartridge into the associated diagnostic device, the 
Astute140® Meter, that exploits a “fluorecence detection technology to quantitatively measure 
biomarkers of acute kidney injury in human urine samples”. 
The NephroCheck® Test represents a promising diagnostic device that could potentially 
fulfil the following objectives. Firstly, it signals which patients have an increased risk of 
developing AKI. Secondly, it allows a stratification of patients, distinguishing those that have 
a lower risk form those having a greater risk of developing AKI in the subsequent 12 hours. 
For this purpose, two clinical cut-offs have been defined (see Kashani et al. 2013, and Hoste 
et al. 2014). A lower cut-off of 0.3 allows early recognition of most patients that are at risk of 
developing AKI. Therefore, 0.3 is intended to be used in routine clinical practice as a signal to 
start those measures and undertake mild management strategies, which promote adaptive 
renal recovery and may prevent progression to chronic disease, as outlined in the KDIGO 
guidelines3 (see Figure 2.4). A higher cut-off of 2.0 identifies individuals that are at the 
highest risk of AKI, for whom more active kidney sparing interventions may be appropriate. 
																																																								
3 For more details see kdigo.org/home/guidelines/acute-kidney-injury/ and kdigo.org/home/guidelines/ckd-
evaluation-management 
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AKD: Acute Kidney Diseases and Disorders, AKI: Acute Kidney Injury, GFR: Glomerular Filtration Rate, PTH: 
parathyroid hormone, RRT: Renal Replacement Therapy. 
Adapted from Ferenbach and Bonventre (2015)  
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Figure 2.4. Conceptual model of AKI to CKD and stage-based 
management of AKI according to KDIGO guidelines.	
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Finally, as already anticipated, awareness of an increased risk enables clinicians to 
undertake nephro-protective measures, to make choices on management and timing of 
therapies, and to implement strategies that can help preserving the kidneys and potentially 
mitigate the adverse outcomes associated with AKI.  
In conclusion, the opportunity to detect AKI early is a precious tool for clinicians, with 
positive impact on patient management and care. On the one hand, biomarkers cannot forecast 
future AKI development, if this event has not happened yet when biomarkers are sampled. On 
the other hand, biomarkers may represent a powerful and robust alert system (also in 
combination with the overall patient’s clinical picture). Clinical cut-offs of 0.3 and 2.0 have, 
indeed, been selected as having, respectively, a high sensitivity and high specificity (see 
Figure 2.5). 
Even if a crucial issue remains on how physicians may realize this potential fully in 
clinical settings, since no specific therapy exists for AKI treatment, at the same time it is 
recognized that delay in AKI diagnosis contributes to ineffective care (Hoste et al. 2014). On 
the contrary, early recognition of the risk affords sufficient time to intervene actively or 
through more kidney-sparing measures, helps reducing the incidence and severity of AKI case 
and avoiding additional exposure to other AKI-causing events (see Hoste et al. 2014, Ronco 
2014, Shaw, Chalfin and Kleintjens 2011). 
Values are calculated for the development of AKI (KDIGO Stage 2-3) 
within 12 hours of sample collection, as a function of 
[TIMP-2] × [IGFBP7] cut-off value in the Sapphire cohort. 
Source: Hoste et al., (2014) 
Figure 2.5 Sensitivity and specificity for [TIMP-2] × [IGFBP7] 
	28	
  
	 29	
3 LOGISTIC REGRESSION AND ROC CURVE ANALYSIS 
3.1 THE LOGISTIC REGRESSION MODEL 
Regression models are often employed in medical research to evaluate the contribution 
of several factors to an outcome of interest. The aim of any regression analysis is to find the 
best fitting, parsimonious but also clinically interpretable model to describe the relationship 
between the outcome (or dependent) variable and a set of independent predictors (called 
explanatory variables or covariates). In many clinical settings, the outcome variable is binary, 
meaning that it takes one of only two possible values representing that an event takes place or 
not, or more generally the presence or absence of an attribute of interest. A logistic regression 
model is the most frequently adopted in the analysis of this type of data (see Hosmer, 
Lemeshaw and Sturdivant 2013). For the purpose of this study, the “event” of interest consists 
of developing/not developing AKI after cardiac surgery and a multiple logistic regression 
model was chosen. 
In a logistic regression, the outcome variable 𝑦 is such that 𝑦 =  1    if the attribute is present0    otherwise.                            𝑦 is the realization of the random variable 𝑌, that can assume value one and zero with 
probability 𝜋 𝒙  and 1- 𝜋 𝒙 , respectively.  
The key quantity to be estimated in the logistic regression, like in any other regression 
model, is the mean value of the outcome variable 𝑌, given the value of a vector of p 
independent predictors 𝒙! = (𝑥!, 𝑥!,… 𝑥!): the conditional mean Ε 𝑌 𝒙 , where 𝒙 represents 
specific values assumed by the independent variables. This quantity – read as “the expected 
value of 𝑌 given 𝒙” – is equal to the conditional probability Pr 𝑌 = 1 𝒙  and must be greater 
than or equal to zero and lower than or equal to one (0≤ Ε 𝑌 𝒙  ≤1)). 
The regression model for 𝑌 is therefore 𝑌 = 𝜋 𝒙 + 𝜀 and the error term 𝜀 can assume two 
values:  𝜀 =  1− 𝜋 𝒙     with probability 𝜋 𝒙          − 𝜋 𝒙          with probability 1− 𝜋 𝒙 . 
In other words, 𝑌 follows a Bernoulli distribution with parameter 𝜋 𝒙 : 
Pr 𝑦|𝒙 = 𝜋 𝒙 ! 1− 𝜋 𝒙 !!! 
(note that the expression is equal to 𝜋 𝒙  if 𝑦 = 1 and to 1− 𝜋 𝒙  if 𝑦 = 0). The expected 
value and variance of 𝑌  conditional on x are Ε 𝑌 𝒙 = 𝜋 𝒙  and var 𝑌 𝒙 = 𝜋 𝒙 1−
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𝜋 𝒙 ,	where Ε 𝑌 𝒙 = Pr 𝑌 = 1 𝒙  is the probability of the event (or the probability that 
the attribute is present). 
 Considering that the model describes a conditional probability, a distribution that 
satisfies the constraint 0≤ Ε 𝑌 𝒙  ≤1 is necessary and the logistic distribution does it. The 
curve of this distribution (represented in Figure 3.1) is S-shaped, delimited from the lines y=1 
and y=0 to which it asymptotically tends.  
 
In particular, 𝜋 𝒙 = 𝑒! 𝒙1+ 𝑒! 𝒙  
is the specific form of the logistic regression model that satisfies the constraint 0≤ E(Y|x) ≤1, 
where 𝑔 𝒙  is the logit transformation of 𝜋 𝒙 : 𝑔 𝒙 = ln 𝜋 𝒙1− 𝜋 𝒙 = 𝛽! + 𝛽!𝑥! + 𝛽!𝑥! +⋯+ 𝛽!𝑥!. 
The logit g(x) is expressed as the natural logarithm of the odds, defined as “the ratio of the 
probability to its complement” (Rodríguez 2007). It has some interesting properties: it is 
linear in its parameter, may be continuous and may range from −∞ to  +∞, depending on the 𝒙. 
 
Figure 3.1. The Logit Transformation. (Source: Rodriguez)	
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3.2 ESTIMATION AND INTERPRETATION OF THE MULTIPLE 
LOGISTIC REGRESSION MODEL 
Fitting a logistic regression model to a sample of n independent observations (𝑥!, 𝑦!) for the i-
th individual, with i=1,2,…,n, requires the estimation of the vector of parameters 𝜷! =(𝛽!,𝛽!,… ,𝛽!) through the method of maximum likelihood, that delivers the values of the 
unknown parameters that maximize the probability of obtaining the observed set of data. This 
method requires the specification of the likelihood function, which expresses the probability 
to observe the realized data as a function of the unknown coefficients. The likelihood function 
is obtained as the product of the contribution for each i-th independent observation (𝑥!, 𝑦!),  𝜋 𝒙! !! 1− 𝜋 𝒙! !!!!, 
so we get 𝑙 𝜷 = 𝜋 𝒙! !! 1− 𝜋 𝒙! !!!!!!!! . 
The log of this expression is computed to obtain the log-likelihood function 𝐿 𝜷 = ln 𝑙 𝜷 = 𝑦!ln [𝜋 𝒙! ]+ 1− 𝑦! ln [1− 𝜋 𝒙! ]!!!! . 
The estimate of β that maximize the expression is obtained by means of differentiating 𝐿 𝜷  
and computing the likelihood equations: 𝑦! − 𝜋 𝒙! = 0!!!!   𝑥!" 𝑦! − 𝜋 𝒙! = 0!!!!   
for j=1,2,..,p. 
The value of β obtained by the solution to these equations is the maximum likelihood estimate 𝜷. 
A key issue is to understand the meaning of the regression coefficients estimated in a 
logistic regression. Apart from the intercept coefficient (in most cases of limited interest), the 
slope coefficients represent the rate of change of a function of the dependent variable per unit 
of change in the independent variable. In a logistic regression model, this function is the logit 
transformation 𝑔 𝒙 = ln ! 𝒙!!! 𝒙 = 𝛽! + 𝛽!𝑥! + 𝛽!𝑥! +⋯+ 𝛽!𝑥! , so that each β is a 
change in the logit, corresponding to a unitary change in the predictor: 𝛽! = 𝑔 𝑥! + 1 − 𝑔 𝑥! . 
A meaningful interpretation of this association is offered in terms of the odds ratio.  
In the simplest case where there is one dichotomous covariate (𝑥 can be either 0 or 1), the 
odds ratio OR is the ratio of the odds for 𝑥 = 1 to the odds for 𝑥 = 0: 
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OR = 𝜋 11− 𝜋 1𝜋 01− 𝜋 0 . 
By substituting the expression 𝜋 𝑥  for 𝑥 = 0, 1   it becomes OR = 𝑒!!. The odds ratio 
indicates how much more likely/unlikely – in terms of odds – it is for the outcome to be 
present (𝑦 = 1) in individuals with 𝑥 = 1 with respect to individuals with 𝑥 = 0. In case of a 
continuous covariate, the interpretation of the odds ratio does not differ much; the crucial 
point is to define a meaningful change in the covariate 𝑥, such that it helps the interpretation 
of how the odds of the outcome changes with the 𝑥. 
 
3.3 LOGISTIC REGRESSION DIAGNOSTICS 
To assess the goodness of fit of the logistic regression model some statistics are 
normally computed, to assess whether the probabilities estimated by the model reflect 
accurately the true outcome pattern in the data. To do so, both overall measures of fit and 
measures of the difference between observed and fitted values 𝑦 − 𝑦 , also graphically, are 
important. Firstly, it is important to define that the expression covariate pattern describes a 
particular configuration of values assumed by the covariates in a model. The number of 
covariate patterns may be an issue when it comes to assess the fit of a model (see Hosmer, 
Lemeshaw and Sturdivant 2013).  
In a model containing p explanatory variables 𝒙! = (𝑥!, 𝑥!,… 𝑥!) and with J possible 
distinct covariate patterns observed for all the n subjects, if some individuals have the same 
value of 𝒙 then 𝐽 < 𝑛. Denoting the number of subjects with 𝒙 = 𝒙𝒋  by 𝑚!, with j=1,2,…J, it 
follows that 𝑚! = 𝑛. If 𝑦! indicates the number of individuals such that  𝑦 = 1, among the 𝑚! subjects characterized by the pattern 𝒙 = 𝒙𝒋, then 𝑦! = 𝑛! is the total number of subjects 
with 𝑦 = 1. 
A first measure of the difference 𝑦 − 𝑦  is the Pearson residual, which measures the 
relative deviations between observed and fitted values. For a generic j-th covariate pattern, the 
Pearson residual is defined as the standardized difference between the observed frequency and 
the predicted frequency 𝑟 𝑦! ,𝜋! = !!!!!!!!!!! !!!!   
and the Pearson chi-square statistic is computed  
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𝜒! = 𝑟 𝑦! ,𝜋! !!!!! . 
Another method is based on the contribution of each point to the likelihood. This is expressed 
by the deviance residual 𝑑 𝑦! ,𝜋! = ± 2 𝑦!ln !!!!!! + 𝑚! − 𝑦! ln !!!!!!! !!!! ! !,   
where the sign is the same of 𝑦! −𝑚!𝜋! . The goal is to minimize the sum of the deviance 
residuals and the corresponding statistic is 𝐷 = 𝑑 𝑦! ,𝜋! !!!!! . 
With grouped data, under the assumption that the fitted model is correctly specified, both 
statistics are asymptotically distributed as a chi-square with 𝐽 − (𝑝 + 1) degrees of freedom. 
A summary measure of goodness of fit is the Hosmer-Lemeshow Test, which is based 
on the idea that the predicted frequency and observed frequency should match closely, and 
that the model fits better as the frequencies match more closely. The test statistic is computed 
as the Pearson chi-square from the contingency table of observed and expected frequencies, 
and the Hosmer-Lemeshow Test yields a large p-value in case of good fit. 
The Hosmer-Lemeshow statistic is computed as 𝐶 = !!!!!!! !!!! + !!!!!!! !!!!!!!! , 
with  𝑜!! = 𝑦!!!!!! , 𝑜!! = 𝑚! − 𝑦!!!!!! , 𝑒!! = 𝑚!𝜋!!!!!! , 𝑒!! = 𝑚!(1− 𝜋!)!!!!!   
and 𝑐! is the number of covariate patterns in the k-th group. 
When the model involves many continuous predictors, the contingency table might get too 
large with the risk of delivering significant results more than often. Therefore, a strategy 
usually adopted consists in splitting the sample in 𝑔 groups according to the predicted 
probabilities (see Hosmer, Lemeshaw and Sturdivant 2013). For example, if g=10 is chosen, 
as usually suggested, for a sample with n observations, then the first group contains a number 
of subjects n/10 having the smallest estimated probabilities. The test statistic approximately 
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follows a chi-square distribution with g−2 degrees of freedom, when the model is correctly 
specified. 
 
3.4 THE RECEIVER OPERATING CHARACTERISTIC CURVE FOR THE 
ANALYSIS OF A DIAGNOSTIC TEST’S PERFORMANCE 
The receiver operating characteristic (ROC) curve is a graphical plot used to assess the 
performance of a classifier. This technique finds wide application in the evaluation of clinical 
diagnostic tests that provide a result in the form of a continuous variable. An ideal test is able 
to discriminate perfectly diseased cases from normal (i.e. healthy) cases, but when this is not 
the case ROC curve analysis measures the accuracy of a test along the range of all possible 
values. In addition to that, ROC analysis allows selecting the best cut-off, the value of the test 
that maximizes the difference between true positives and false positives (D’Arrigo et al. 
2011). 
All these concepts can be better explained with the help of a graphical representation. 
Figure 3.2 illustrates that the distribution of a hypothetical test results for the two groups 
(healthy and diseased) partially overlap, being not able to discriminate perfectly and 
misclassifying some individuals. 
 
Individuals that are incorrectly classified can be either “false negatives” (FN, people 
that the test identifies as negative, thus healthy, when in fact they are positive, thus diseased) 
Figure 3.2 Graphical representation of the proportions of 
TP, TN, FP and FN 
Cut-off	value	
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or “false positives”(FP, people classified as diseased that in fact are healthy) (see also Table 
3.1). 
On the basis of the proportion of individuals classified in the categories illustrated in 
Table 3.1, the power of a diagnostic test is evaluated by computing a series of statistics. Let 
“a” be the number of true positives, “b” of false negatives, “c” false positives and “d” true 
negatives, then: 
• sensitivity = a
a+b
 is the probability that the test result will be positive when the disease 
is present. Also known as the true positive rate, it is expressed as a percentage;  
• specificity = d
c+d
 is the probability that the test result will be negative when the disease 
is not present. Also known as the true negative rate, it is expressed as a percentage. 
Specificity is related to the false positive rate ( c
c+d
 the proportion of FP individuals on 
all the healthy) through the equation specificity = 1 – fp rate; 
• positive predictive value (PPV) = a
a+c
 is the probability that the disease is present when 
the test is positive; 
• negative predictive value (NPV) = d
b+d
 is the probability that the disease is not present 
when the test is negative; 
• accuracy = a+d
a+b+c+d
 is the proportion of patients correctly classified. 
 
Table 3.1. Contingency table for test results against the disease state. 
 
Disease 
Present Absent 
Test Result 
Positive True Positive (TP) 
a 
False Positive (FP) 
c 
Negative False Negative (FN) 
b 
True Negative (TN) 
d 
 
Differently from the PPV and the NPV, sensitivity and specificity are independent of 
the disease prevalence, in other words, they do not depend on the number of disease cases in 
the population of interest (D’Arrigo et al. 2011). 
The ROC curve plots, in a two-dimensional plane, the sensitivity (on the y axis) as a 
function of the false positive rate (1 – specificity, on the x axis) for different cut-off points. 
This graphical representation illustrates the trade-offs between the TP (benefits of the test) 
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and the FP (costs of the test) for every point on the curve, each one representing a possible 
decision threshold. The more to the northwest of the graph a point lies, the higher is the 
accuracy of the associated threshold value because it is further from a random classification 
(represented by the dotted line in Figure 3.3). The area under the curve (AUC) measures the 
overall accuracy of the test: the greater the AUC, the better the discriminating performance of 
the test. An ideal test would have au AUC of 1, in practice this is very difficult to obtain and a 
good test should have AUC≥0.8. 
 
  
Figure 3.3. Basic ROC curve representation on the xy plane. 
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4 ADVERSE OUTCOMES AND COSTS ASSOCIATED WITH 
ACUTE KIDNEY INJURY 
Acute kidney injury (AKI) is a serious and common problem among hospitalized 
patients and it is a recognized complication particularly following cardiac surgery, where 
incidence can reach 40-50% (see Mariscalco et al. 2011 and Shaw, Chalfin and Kleintjens 
2011), and in intensive care unit (ICU) where approximately one out of four patients is 
diagnosed AKI (De Smedt et al. 2012). On the basis of single-centre reports, Chertow et al. 
(2005) report that 5% to 7% of all hospitalized patients develop AKI. However, many studies 
conduced so far recorded a variable AKI incidence, because different AKI definitions were 
adopted in the past. Wide ranges for AKI incidence are, thus, due to the lack of unique and 
widely accepted classification criteria based on serum creatinine (SCr), until the KDIGO 
criteria were released in 2012 with the aim of building clinical practice guidelines for AKI 
and a benchmark for AKI definition and classification4. Adoption of a uniform definition is 
necessary also to make results from different studies comparable. 
Failure to identify, diagnose and classify AKI timely is a serious issue because of the 
adverse outcomes that arise even in case of mild AKI cases (Kerr et al. 2014); in more severe 
cases, where kidney fails and dialysis treatment is necessary, 30% to 50% of patients die (see 
Taylor 2011). Allowing AKI to progress may lead to negative short- and long-term outcomes 
for the patient, such as increased morbidity, both in-hospital and post-discharge increased 
mortality, need for renal replacement therapy (RRT) and, eventually, possible progression to 
chronic kidney disease (CKD). Identification of risk factors, careful patient monitoring, 
timely and appropriate start of required therapies are necessary to reduce AKI risk and 
subsequent deterioration of patient conditions. 
The lack of a consensus definition and classification criteria, so far, has not only 
hampered clinical judgement and prompt intervention, but has also made it difficult to 
estimate resource use associated with AKI and its impact on healthcare costs (see Dasta et al. 
2008). Nevertheless, in this chapter some findings will be presented concerning the estimation 
of costs related to AKI, not only in terms of resource use and costs during hospitalization, but 
also long-term costs and adverse clinical outcomes. In doing so, the aim is to delineate a 
																																																								
4 For more details on KDIGO guidelines for AKI definition and classification and on previously adopted criteria 
see  Chapter 2. 
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framework to help understanding the burden of AKI, as well as the urgent need for effective 
AKI detection methods. 
 
Direct assessment of AKI-related costs and outcomes has taken place mostly at single-
centre level. Hereafter are presented some findings drawn from the work of Kerr et al. (2014), 
who estimated the economic impact of AKI, using data on hospital episode statistics (HES) 
and reference costs in England for the period 2010-11, as well as data from academic studies. 
Previous attempts to estimate consequences and AKI associated costs were made by Chertow 
et al. (2005) at an academic medical centre in Boston and by Dasta et al. (2008), who 
quantified the total postoperative costs associated with AKI following CABG surgery at 
Pittsburgh Medical Centre. 
A relatively extensive literature exists, as far as costs of dialysis is concerned, also for 
patients who need dialysis treatment as result of developing AKI during hospitalization. Costs 
and outcomes associated with dialysis will also be briefly reported in the following 
paragraphs. 
 
4.1 ADVERSE CLINICAL OUTCOMES ASSOCIATED WITH ACUTE 
KIDNEY INJURY 
4.1.1 SHORT-TERM OUTCOMES 
All AKI patients, even those who experience milder cases, have longer hospital stays, a 
fact that makes AKI an expensive condition. In their study, Kerr et al. (2014) extrapolated 
some data from academic studies (more precisely, from East Kent Hospitals University 
Foundation Trust EKHUFT), in addition to data collected through HES. The reason why these 
additional analysis were deemed necessary is that AKI has been traditionally under 
recognised and under coded in hospital routine datasets, a fact that might be due to the already 
cited lack of uniform definition and classification of AKI. In particular, Kerr et al. (2014) 
suggested that hospital data are more likely to record the severe cases, thus underestimating 
the actual incidence of AKI. Indeed, approximately 70% of the AKI cases recorded in 
EKHUFT data were AKI stage 1 (according to AKIN classification criteria) and 15.33% of all 
hospital admissions were characterized by an AKI case (any severity). Conversely, HES 
recorded AKI in only 2.43% of all hospital admissions, confirming that HES data 
underestimate actual AKI incidence and prevalence. 
In terms of hospital length of stay, HES data reported length of stay for AKI patients 
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which is 2.57 times as long as for other patients, on average. In EKHUFT data, conversely, 
individuals who developed AKI experienced a length of stay 1.62 times that of non-AKI 
patients; additionally, it was shown that length of stay increases along with AKI severity (see 
Table 4.1). 
Besides longer hospital stays, AKI inpatient care is associated with more intense 
resource use, in particular in the form of excess critical care bed days. The cost of a critical 
care bed day is higher as compared to other departments bed days and, for the AKI 
population, the analysis pointed out a critical care bed day usage 4.32 times the usage for 
patients without AKI (Kerr et al., 2014). 
As previously mentioned, AKI is associated also with increased in-hospital mortality. 
Data from HES reported that 28.11% of AKI patients died before discharge and the relative 
risk5 with respect to non-AKI patients is 4.69. The percentage drops to 13.93% according to 
EKHUFT data (relative risk is 3.50), which might due to the fact that academic studies 
recognised also less severe AKI cases. The findings extrapolated from EKHUFT data are 
summarized in Table 4.1 below. 
 
Table 4.1. LOS, critical care days and in-hospital mortality by AKI status, EKHUFT data 
 No AKI All AKI AKIN 1 AKIN 2 AKIN 3 Unknown 
LOS      
Mean (SD) 4.5 (10.5) 10.72 (15.44) 9.7 (14.6) 12.3 (16.0) 14.9 (18.5) 2.3 (9.8) 
Ratio 1 1.62 1.52 1.88 2.16 0.45 
Critical care      
Mean (SD) 0.05 (1.02) 0.35 (2.35) 0.17 (1.74) 0.31 (1.80) 1.57 (4.78) 0.02 (0.51) 
Ratio 1 4.32 2.60 5.61 18.2 0.02 
In-hospital mortality      
% mortality 2.00 13.93 8.10 25.60 33.30 1.97 
Relative Risk 1 3.50 2.11 5.79 8.94 1.31 
All values are statistically different (p-value<0.001). 
AKI: acute kidney injury; LOS: length of stay. 
(Source: adapted from Kerr et al., 2014) 
 
 																																																								
5 Relative risk is defined as the ratio between cumulative incidence in the exposed group (AKI patients) and 
cumulative incidence in the unexposed group (non-AKI patients). 
	40	
Taylor (2011) reported some numbers from the Manchester University Foundation 
Trust that are in line with the framework drawn by Kerr et al. (2014) based on EKHUFT data. 
Incidence of AKI was 23.5%, with a median length of stay of 17.8 days in the AKI group and 
6.8 days in the non-AKI group. Additionally, 11.5% AKI patients required critical care, 
compared to only 2% of the remaining group of patients. As far as in-hospital mortality is 
concerned, 5.6% of AKI patients and 1.37% of non-AKI patients died before discharge. These 
findings suggest that if AKI incidence were reduced by 10%, then Manchester University 
Foundation Trust could save as many as 5,000 bed days. 
 
4.1.2 LONG-TERM OUTCOMES 
AKI is associated not only with higher in-hospital mortality and need for additional 
treatments during hospital stay, but also with longer-term adverse outcomes, such as 
increased mortality risk and higher risk of progression to CKD. 
Kerr et al. (2014) found out from EKHUFT data that 90 days following discharge 
0.56% of AKI patients were on RRT. After excluding those patients that might have anyway 
progressed to CKD requiring dialysis even in the absence of AKI, because they already 
presented CKD stages 4-5, then 0.26% of patients who developed AKI required RRT 90 days 
after discharge. 
Pannu et al. (2013) analysed renal outcomes among patients who survived AKI 
(KDIGO stage 2 or 3), defining renal recovery as a post-AKI SCr within 25% of the baseline 
(pre-hospitalization). 3,231 patients were followed after discharge over a 34-month period: 
30.8% of AKI survivors died and 2.1% progressed to kidney failure (CKD stage 5). 
Additionally, participants who did not recover renal function had higher risk of mortality and 
adverse renal outcomes (such as progression to CKD), as measured by hazard ratios (HR)6 in 
comparison with patients who recovered kidney function: mortality HR was estimated at 1.26 
and adverse renal outcomes HR at 4.13. 
 
4.1 AKI-ASSOCIATED COSTS 
When it comes to evaluating the economic impact and financial burden of AKI, the 
main problem is certainly the absence of a uniform definition of AKI and, consequently, an 																																																								6	Hazard Ratios measure the instantaneous risk at a particular time. They differ from risk ratio in the sense that 
the latter describe a cumulative risk. 
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accurate estimate of AKI incidence (see Chertow et al. 2005). Nevertheless, some single-
centre studies have been conducted, so far, with the aim of evaluating AKI-associated costs. 
Before summarizing the main findings that can be drawn from these researches, it is worth 
noting that many of them actually focused on rather tightly defined patient groups, such as 
patients developing AKI after cardiac surgery or CABG (Coronary Artery Bypass Graft), and 
that additional research should be done to extend findings to a more heterogeneous population 
(see Lewington and Hall 2014). Besides this fact, Lewington and Hall (2014) also argue that 
one limitation of these studies is that AKI-related cost may not be fully AKI-attributable cost: 
to capture the actual burden of AKI, it would be important to discern those costs that would 
have occurred also in the absence of AKI. The same reasoning applies also in case of lifetime 
post-discharge costs of care for patients who developed AKI during hospitalization. 
Dasta et al. (2008) quantified the total postoperative costs and resource usage associated 
with AKI following CABG surgery, classified according to RIFLE criteria7; this study 
provided also an insight on clinical outcomes deriving from AKI, such as length of stay, need 
for RRT and hospital mortality. Costs and outcomes of 258 AKI patients were compared to a 
control group of patients, matched on the basis of preoperative (baseline) characteristics. 
Estimation of costs focused on the postoperative period, so preoperative treatments were not 
included. 	
Table 4.2. Costs and outcomes of patients with and without AKI after CABG (2002 $) 
 Postoperative 
costs 
ICU costs Postop. LOS 
(days) 
ICU LOS 
(days) 
RRT 
(%) 
Mortality 
(%) 
AKI patients 
n=258 
$37,674 
(23,654–68,433) 
$25,949 
(15,47–59,175) 
11.0 
(7–18) 
3.2 
(1.5–6.5) 
3.5 11.2 
Controls 
n=258 
$18,463 
(14,704–23,822) 
$13,836 
(11,165–19,923) 
5.0 
(4–7) 
1.4 
(1.1–2.0) 
0.4 2.3 
Medians (interquantile ranges). All values are statistically different (p-value<0.001). 
AKI: acute kidney injury; ICU: intensive care unit; LOS: length of stay; RRT: renal replacement therapy. 
(Source: adapted from Dasta et al., 2008) 	
As Table 4.2 displays, costs and adverse clinical outcomes for AKI patients were 
significantly higher than those for control patients. The 258 patients with AKI generated a 
cumulative cost of $18.3 million. Findings concerning length of stay, requirement for RRT 																																																								
7 See Chapter 2 for a description of existent classifications for AKI. 
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and mortality show that these negative clinical outcomes statistically increase in AKI patients; 
all these results are in line with those of previously cited studies.  Moreover, Table 4.3 reports 
resource usage and clinical outcomes stratified by RIFLE categories, showing how costs 
significantly rise as AKI gets more severe (from RIFLE-R to RIFLE-F category); in a similar 
way, clinical outcomes get worse. It appears clearly that the main driver in postoperative costs 
is the prolonged length of stay and the need for critical care assistance: ICU costs represent 
between 73.3% and 93.7% of total postoperative costs, depending on severity of AKI. 
 
Table 4.3. Resource usage and outcomes of three RIFLE categories  
in patients with AKI after CABG (2002 $) 
 RIFLE-R RIFLE-I RIFLE-F 
Incidence (%) 53.5 27.1 19.4 
Total postoperative costs $29,697 
(20,041–52,351) 
$38,924 
(25,092–70,424) 
$52,618 
(35,250–91,954) 
ICU costs $21,775 
(13,444–41,427) 
$28,872 
(17,961–63,322) 
$49,328 
(21,454–83,687) 
ICU costs (% of total costs) 73.3 74.2 93.7 
Total postoperative LOS days 9 (6-17) 11 (7-19) 16 (12-25) 
ICU LOS days 2.29 (1.34–5.2)  3.45 (1.9–7.7)  5.42 (2.8–12.3) 
ICU LOS days (% of total LOS) 25.4 31.3 33.8 
Medians (interquantile ranges). All values are statistically different (p-value<0.001). 
AKI, acute kidney injury; ICU, intensive care unit; LOS, length of stay. 
(Source: adapted from Dasta et al., 2008) 	
Chertow et al. (2005) analysed data from Brigham and Women’s hospital, a medical 
centre in Boston, to show that even small changes in Serum Creatinine (namely, changes of 
SCr > 0.3 mg/dl) were associated with increased hospital length of stay, mortality and costs, 
with respect to a group of controls. Main study results, as regarding costs estimates, are 
displayed in Table 4.4. 
Total annualized hospital costs for the recorded AKI patients represent 5% of total 
hospital costs and, more interestingly, also milder cases of AKI (non requiring dialysis) 
caused a substantial financial burden that cannot be ignored from a public health perspective 
(Chertow et al., 2005). 
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Table 4.4. Costs associated with selected changes in SCr 
Criterion for SCr change (n) Mean Increase in 
Total Cost ($) 
é SCr ≥ 0.3 mg/dl (2892) $8,902  
é SCr ≥ 0.5 mg/dl (1236) $12,656 
é SCr ≥ 1.0 mg/dl (351) $21,475 
é SCr ≥ 2.0 mg/dl (105) $33,161 
é SCr by 25% (4060) $7,469 
é SCr by 50% (1967) $10,125 
é SCr by 100% (714) $15,192 
é SCr by 50% to a minimum peak 
     of 2.0 mg/dl (352) 
$19,517  
é SCr≥0.5mg/dl with baseline SCr<2.0mg/dl or 
é SCr ≥1.0 mg/dl with baseline SCr≥2.0 and  
<5.0 mg/dl (1160) 
$13,451 	
Results are relative to those without the change indicated, on a total sample of 
n=9205. SCr: serum creatinine. 
(Source: adapted from Chertow et al., 2005)	
 
In the already cited study of Kerr et al. (2014), the economic impact of AKI to the 
National Health System (NHS) in England for the year 2010-11 was estimated, exploiting 
data from HES and academic studies (EKHUFT). Cost estimation deriving from HES data 
were based on Healthcare Resource Group (HRG) tariffs – HRG are groups of health care 
activities to which a patient admission is assigned according to diagnosis and interventions. A 
first important finding is that AKI related costs deriving from HES data tend to underestimate 
the actual AKI economic burden, not only because of the under-recognition of AKI cases 
typical in HES data, but also because only 16.22% of AKI recorded cases were grouped to a 
HRG representing AKI, leading to an estimated cost of £75 million. The remaining patients 
who developed AKI were attributed to a different HRG, reflecting the fact that AKI often 
comes along with other illnesses and interventions. Costs related to these admissions were 
calculated according to the excess days of hospitalization related to AKI, for a total additional 
cost of £304 million. Total inpatient expenditure associated to admissions recording an AKI 
event amounted, thus, to £380 million. Nevertheless, this estimate is still likely to undervalue 
the actual AKI-associated cost, because it is based on average cost per bed day for a 
“standard” patient and excludes critical care use. In-patients care for an individual who 
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develops AKI, however, might be more expensive due to medications, intensive care and 
additional therapies required, such as RRT in worst cases. Moreover, this estimate excludes 
the cost of post-discharge care. 
According to Kerr et al. (2014) records from EKHUFT are probably more 
representative of actual AKI incidence in England (15.33% of total hospital admissions, as 
compared to 2.43% in HES data). If this were actually the case, then inpatient expenditure 
related to AKI would amount to £1.02 billion in England, plus post-discharge care costs of 
£179 million, for a total cost of care of £1.2 billion. Additional long-term costs arising after 
discharge are due to a higher incidence of CKD and RRT in patients who developed AKI, as 
compared to non-AKI patients. Table 4.5 below reports how total care costs are computed, 
based on HES data and on extrapolations from EKHUFT academic studies. 
 
Table 4.5. Estimated expenditure related to AKI, England 2010–11 
 HES data Extrapolation from EKHUFT 
Admissions to AKI HRG £75,186,389 £75,186,389 
Excess LOS in other HRGs £304,364,710 £750,463,603 
Critical care No data available £198,232,502 
Total inpatient care £379,551,099 £1,023,882,494 
Post-discharge care No data available £179,345,543 
Total Care £379,551,099 £1,203,228,037 
LOS: length of stay; HRG: Health Resource Group 
Source: adapted from Kerr et al. (2014) 	
Based on these findings, the financial burden of AKI amounted to 1% of total NHS 
budget in England during 2010-11. The scope for cost savings is substantial in this 
framework. According to NCEPOD report in the UK, Kerr et al. (2014) argued that 20% of 
AKI cases are avoidable. If so many AKI cases were actually prevented, then savings to the 
NHS would amount to £200 million (0.2% of the total NHS budget in England). 
 
4.2 COSTS OF RENAL REPLACEMENT THERAPY AND LONG-TERM 
DIALYSIS DEPENDENCE FOLLOWING ACUTE KIDNEY INJURY 
As previously mentioned, in the most severe cases AKI may require the provision of a 
RRT. Indeed, as many as 4-5% of critically ill patients require such therapy during their ICU 
stay, following AKI (see Manns et al. 2003). Two major modalities of RRT can be 
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distinguished: continuous RRT (CRRT) and intermittent RRT (IRRT). Each of the two 
modalities has a set of advantages and disadvantages; each patient may be a candidate for 
either therapy, depending on his/her characteristics and disease, and the way in which the two 
therapies are provided can vary widely across regions, due to availability, costs, physicians 
expertise, hemodynamic stability and the primary purpose of the procedure (fluid removal or 
solute clearance). So far, there seems to be no clear evidence about which, if any, of the two 
therapies delivers the higher survival rate (see Srisawat et al. 2010, and Mazairac et al. 2013). 
Assessment of the outcomes and costs of different RRT is deemed necessary due to high 
mortality, morbidity and costs associated with AKI and its treatment, in order to allow an 
efficient allocation of resources.  
Hereafter are presented the findings of some studies that focused on the costs of 
dialysis. Most of them compared different dialysis treatments and are useful to get an insight 
into the costs arising from AKI that necessitates RRT. 
RRT is associated with significant higher hospital costs, longer hospitalization and 
increased mortality rates as compared to AKI patients not requiring RRT, as Table 4.6 below 
shows. From these results provided by the research of Dasta et al. (2008) it is clear that costs, 
length of stay and days in ICU are more than double, on average, for patients who need RRT 
after AKI, as compared to AKI patients that do not need such treatment. 
 
Table 4.6. Effects of RRT on costs and outcomes in patients with AKI after CABG (2002 $) 
 Total postop. 
costs 
ICU costs Total postop. 
LOS (days) 
ICU LOS 
(days) 
Mortality 
(%) 
Cases with RRT 
n=27 
$74,040 $71,511 21.0 6.7 37.0% 
Cases without RRT 
n=231 
$34,953 $23,880 10.0 2.7 8.2% 
Controls 
n=258 
$18,463 $13,836 5.0 1.4 2.3% 
Median values. All values are statistically different (p-value<0.001). 
AKI: acute kidney injury; ICU: intensive care unit; LOS: length of stay; RRT: renal replacement therapy. 
(Source: adapted from Dasta et al., 2008) 
 
De Smedt et al. (2010) looked at treatment modalities for AKI with the purpose of 
determining the preferable method, accounting for the associated health costs. The authors 
considered not only CRRT and IRRT, but also a conservative (CONS) therapy that did not 
encompass dialysis. The authors found that CRRT was the most expensive treatment with a 
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mean total cost (including hospitalization costs and follow-up costs over a two-year period) of 
€51,365, and that both RRT lead to additional expenditure between €9,643 and €17,563 
compared with CONS (mean total cost €33,802). However, the additional cost of a RRT in 
comparison with CONS (or of one type of RRT with respect to the other) should be evaluated 
together with the benefits associated with each therapy (improvement in clinical outcomes, 
reduction in downstream costs etc.). 
Many patients recover renal function after developing AKI but not all of them. Given 
the high number of critically ill patients who require RRT, failure to recover kidney function 
and progression to end-stage kidney disease (ESKD) that leads to dialysis dependence 
represents a relevant medical and economic issue. 
Recently, Ethgen et al. (2015) hypothesized that the choice of initial treatment of AKI – 
namely, CRRT or IRRT – could influence long-term outcomes in terms of dialysis 
dependence. In particular, based on a recent meta-analysis and systematic review from 
Schneider et al. (2013), the authors investigated the possibility that initial treatment with 
CRRT could be associated with a lower rate of dialysis dependence among survivors and, 
consequently, could be economically superior to IRRT. First of all, it should be noted that the 
upfront cost of CRRT is higher than IRRT – daily cost is respectively $858 and $226, as 
estimated by Manns et al. (2003). Ethgen et al. (2015) reported results of other studies that 
estimated, among patients affected by AKI, a rate of survival of 37% at 180 days from 
discharge and a rate of dialysis dependence at 3 years of 21.7 with CRRT and 26.6 with 
IRRT. Consequently, a five-year cost-effectiveness analysis showed that, despite the lower 
upfront average cost of IRRT, the total cost over a five-year time horizon was higher for 
IRRT patients as a result of the greater rate of dialysis dependence – meaning that CRRT is 
cost-effective as compared to IRRT (five-year ICER of CRRT with respect to IRRT is –
$116,121). 
However, these results appear in contradiction with previous studies that found no 
health or economic advantage of CRRT over IRRT, so there still seems to be no clear-cut 
evidence in favour of either treatment modality. 
 
4.3 IS ACUTE KIDNEY INJURY AN AVOIDABLE COMPLICATION? 
From the results presented in the previous paragraphs, it appears clearly that AKI has a 
substantial economic burden, deriving from longer hospital stays, need for critical care and 
RRT, as well as from long-term adverse clinical outcomes. 
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However, recent debates have focused on the idea that AKI is, in many cases, an 
avoidable complication: even 20% to 30% of AKI cases are predictable and avoidable, 
making the high incidence of this disease unacceptable (Kerr et al. 2014, and Taylor 2011). 
Of course this requires accurate monitoring of patient’s physiological parameters (including 
those related to kidney functions) and possibly calculation of risk scores; clinicians should be 
trained so that they are capable of implementing the appropriate measures, such as reviewing 
medications if necessary, suspending nephrotoxic drugs, ensuring proper patient’s hydration, 
treating infections and other illnesses promptly. Consulting a specialist should also be highly 
recommended in case a patient develops AKI, in order to define promptly a therapy and 
ensure he/she is treated properly. Many AKI cases, indeed, are mild and associated with the 
temporary loss of 20-30% of kidney function and could be treated more effectively when 
identified and addressed early. 
According to Lewington and Hall (2014), attributing causality to AKI for mortality and 
additional costs is fundamental to target interventions aimed at reducing the burden of AKI. 
Anyway, early detection and timely intervention may lead to substantial savings: as Kerr et al. 
(2014) estimated, if 20% of AKI cases where prevented, these savings to the NHS in England 
could amount to £200 million (0.2% of the total NHS budget). 
On the one side, implementing prevention principles, adopting basic measures of care 
and ability to recognize risk of kidney injury on behalf of non-specialists are certainly crucial 
steps in AKI prevention. On the other side, diagnostic innovations and screening methods 
offer a massive opportunity for the early detection of AKI. In this setting, new biomarkers and 
diagnostic tests based on them, such as the NephroCheck® Test, may play a crucial role, in 
that they may allow quick recognition of AKI. Indeed, the NephroCheck® Test may signal 
increased risk of AKI as soon as 12 hours after cardiac surgery and 24 to 48 hours before SCr 
increases. 
 
The following chapter will present the results arising from the retrospective study that 
took place AT the San Bortolo Hospital of Vicenza, with the aim of evaluating the 
NephroCheck® Test as a diagnostic tool for AKI on a population of patients undergoing 
cardiac surgery. 
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5 PREDICTING THE PROBABILITY OF DEVELOPING 
ACUTE KIDNEY INJURY AFTER CARDIAC SURGERY 
5.1 STUDY DESIGN AND AIM OF THE STUDY 
The aim of this dissertation is to evaluate the predictive ability of the NephroCheck® 
Test for an early diagnosis of AKI in patients undergoing cardiac surgery (CSA-AKI: Cardiac 
Surgery-Associated AKI). A necessary step consists in comparing the efficacy and timeliness 
of the diagnosis of CSA-AKI with the NephroCheck® Test to the current methods based on 
Serum Creatinine (SCr). To do so, we analysed a population of patients at risk of developing 
AKI for whom the NephroCheck® Test was not available and another sample of patients with 
comparable epidemiological and clinical characteristics, on whom the NephroCheck® Test 
was used. The accuracy of the diagnostic test was assessed by means of computing the area 
under the receiver operating characteristic curve (ROC curve) and other measures of 
performance. 
Similarly to most innovative technologies, the NephroCheck® Test is an expensive tool, 
especially if compared to current diagnostic methods that are already part of clinical routine 
analysis based on SCr and urine output. Therefore, even if it is effective, it might be 
excessively resource consuming to be used on a routine basis, especially considering the 
current trend characterized by cuts in healthcare spending. This innovation could 
consequently be employed more parsimoniously, in all those cases where there is a higher risk 
of developing AKI and a timely diagnosis could allow interventions that prevent or limit 
progression of the disease. The identification of such cases, within a broader population of 
patients presenting some risk of developing AKI, can take place by building a model for AKI 
prediction and defining a rule for selecting those cases where the NephroCheck® Test should 
be used. Alternatively, introducing the NephroCheck® Test in the clinical routine may deliver 
substantial advantages, in terms of early AKI diagnosis and detection, that could allow more 
careful management of all patients at risk. This means that some AKI cases might be avoided, 
disease severity might be lowered and intervention might prevent disease progression in the 
worse situations, thus ultimately leading to cost savings. Investments required to employ the 
NephroCheck® Test on a routine basis could be then offset by the lower resource 
consumption in patient care related to AKI. 
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5.2 STUDY SAMPLE AND DATA COLLECTION 
For the purpose of this dissertation two cohorts of patients undergoing cardiac surgery 
in the San Bortolo Hospital of Vicenza were considered. First of all, the base model was 
developed on a sample of cardiac surgery patients during the second semester of 2014; then, 
another group of patients that underwent elective cardiac surgery along 2015 and for whom 
the NephroCheck® Test was available was considered. The protocol of the study was 
presented to and approved by the local Ethical Committee at the San Bortolo Hospital of 
Vicenza.  
The selection of patients to be included in the study followed the criteria that are 
described here. Inclusion criteria consisted of selecting (a) only 18 years or older individuals 
(b) who underwent cardiac surgery procedures. Patients were, however, excluded from the 
study if (c) they underwent a surgery procedure of TAVI type (Transcatheter Aortic Valve 
Implantation) (d) they were already receiving a dialysis treatment at the moment of 
hospitalization. 
For the 2014 cohort, the data of 332 patients were collected. For the 2015 cohort, the 
patients had to give their prior informed consent to undergo an additional medical 
examination (the NephroCheck® Test), consisting of a urine test at several time points before 
and after surgery. Samples for the NephroCheck® Test assessment were collected at hospital 
admission (baseline), 30 minutes after the initiation of ECC (extra-corporeal circulation, a 
type of surgical procedure), at CS-ICU (cardiac surgery intensive care unit) admission, 4 
hours, 12 hours and 24 hours after surgery, at hospital discharge and, finally, during a follow-
up that took place after three months. Therefore, patients that underwent urgency or 
emergency surgery could not be included: only patients operated on an elective list and giving 
their informed consent to the additional test were enrolled in the 2015 cohort, for a total of 
110 patients. 
All data were collected according to a case report form in Excel format. The case report 
form was drawn up by a team of physicians and biologists, on the basis of experience, 
knowledge and existing literature on the topic, in order to include the parameters that had 
already been shown to or are expected to correlate with AKI. These parameters include 
anamnestic characteristics of the patients, pre-operative treatments (within 7 days before 
operation), surgery procedure, post-operative treatments and clinical data (up to 24h after 
surgery). 
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The 2014 cohort was then used to develop a model for predicting AKI after cardiac 
surgery. The model included, as explanatory variables, anamnestic and preoperative 
information as well as data on intra- and postoperative therapies. The aim was to build a 
logistic regression model for predicting the probability that a patient develops AKI after 
cardiac surgery, based on the aforementioned features. This model was then applied to the 
2015 cohort and a variable containing the results from the NephroCheck® Test was added to 
it. This allowed to assess if the NephroCheck® Test improves predictive ability of the model 
compared to the base model, which does not account for the NephroCheck® Test results. 
The outcome and explanatory variables considered in the regression models to be 
estimated are listed and described in the following paragraphs. 
 
5.3 OUCOME VARIABLE AND INDEPENDENT PREDICTORS  
The aim of this analysis is to estimate the probability Pr 𝑌 = 1 𝒙  that an event Y 
occurs, depending on p explanatory variables 𝒙! = (𝑥!, 𝑥!,… 𝑥!)  that might be either 
categorical or continuous predictors.  
 Hereafter, the outcome variable Y and the covariates are described in details. 
• The dependent variable 𝑌 is akipost: AKI development after cardiac surgery (within 
10 days). It is a binary variable, coded as 1 if the patient develops AKI and 0 if he/she 
does not. For the purpose of this dissertation, development of AKI was calculated 
according to the serum creatinine (SCr) criteria described in Table 2.2, Chapter 2: 
baseline creatinine is the lowest SCr value recorded during the whole hospitalization 
period and an increment of ≥0.3 mg/dl, occurring within 10 days after cardiac surgery, 
was considered for recording an AKI event.  However, the first post-operative SCr 
measurement, which takes place at intensive care unit (ICU) admission, was not 
considered for the purposes of detecting all AKI cases. The reason is that the blood 
(more specifically, plasma) concentration of creatinine could be affected downward by 
the hemodiluition resulting from the intraoperative infusion therapy. Considering this 
SCr value may, therefore, lead to “over-identification” of AKI events, in other words, 
to the identification of more events than actual AKI cases according to KDIGO 
criteria. 
The covariates included in the final model are the following: 
• akipre is a dichotomous predictor that assumes value of 1 if the patient develops AKI 
before undergoing cardiac surgery, during hospitalization. A patient that has just 
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developed AKI may be susceptible to subsequent renal injuries, since his/her kidneys 
have recently experienced stressful conditions. As described later on in this chapter, 
very few patients developed preoperative AKI, as it is more likely to occur in most 
severe cases. 
• female is another binary covariate that describes the gender category (1 if the patient is 
female, 0 if male). 
• agecut2: patient’s age. Firstly considered as a continuous variable, age was then 
converted into age groups because the risk of developing AKI is likely to increase 
with age in a non-linear way. In particular, it was decided to divide the cohorts of 
patients into three age groups, since AKI risk might increase substantially after the age 
of 65 and even more around the age of 75.  Age groups are defined for individuals 
younger than 65 (reference group), individuals with an age between 65 and 74 
(extremes included), and patients who are 75 or older. 
• obese: a binary variable that takes value 1 if the patient is affected by obesity, as 
calculated through the body mass index (BMI) formula at the moment of 
hospitalization. The BMI is defined as the body mass divided by the square of the 
height (expressed in units of kg/m2). If BMI assumes a value above 30, then the 
subject is considered obese. This covariate might be considered a proxy for a more 
general anamnestic health status, since other dysfunctions or metabolic disease are 
likely to be present along with obesity (such as dyslipidaemia, hypertension, diabetes 
etc.). Other variables denoting an individual’s health status were also considered at the 
beginning of the analysis, but they were excluded from the final model either because 
uninformative – sometimes due to the high rates of missing values or misreporting – 
or because they turned out to be statistically not significant in the univariate and/or 
multivariate regression model. However, the basic idea that lies behind the inclusion 
of this variable is that more severe health conditions are likely to be positively 
correlated with AKI. 
• ckdanamnesi indicates if the patient, at hospitalization, has a moderate to severe form 
of chronic kidney disease (CKD)8. As mentioned previously in this chapter, dialysed 
patients (CKD Stage 5) were excluded from the study sample. This variable is binary 
and, consequently, is coded as 1 if the patient presents a CKD Stage 3 or 4, 0 
otherwise. 																																																								
8 See Chapter 2, Table 2.1, for CKD (chronic kidney disease) classification criteria. 
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• surtype: type of surgery. This is a categorical variable, obtained from several binary 
variables indicating which surgical procedure was employed. In particular, it tells if 
the patient underwent only a “single heart valve (aortic, mitral or tricuspid) surgery 
procedure” (0, svalve), only a “multiple heart valve surgery” (1, multvalve), “CABG 
(Coronary Artery Bypass Graft) surgery” (2, cabg) and “replacement of the ascending 
aorta” (3, aorta). Different surgery procedures may affect in a different way the 
severity of patient conditions, the treatments required after surgery and the risk of 
renal complications, which might be particularly high in the case of bypass procedures 
(see Mariscalco et al. 2011, and Mao et al. 2014). Indeed, patients that undergo CABG 
surgery have severe coronary heart disease, which can reduce blood flow to the 
kidney, eventually causing kidney failure if untreated. 
• eccdur: is a continuous variable that describes the duration of the ECC (Extra-
Corporeal Circulation), expressed in minutes. The ECC is a procedure that consists of 
diverting a patient’s blood flow through an artificial circuit and pumping the blood 
back into the patient’s body. Cardiopulmonary bypass, extracorporeal membrane 
oxygenation and hemodialysis are some of the most common forms of ECC. It is a 
well-known risk factor for postoperative AKI (Jorge-Monjas et al. 2009, and Mao et 
al. 2014) since its duration is likely to correlate positively with the risk of developing 
AKI. 
• postcrea: this is the value of postoperative SCr that was excluded for the purpose of 
defining the outcome variable, as described earlier in this chapter. The value of this 
variable is influenced by many factors, not only those that commonly affect SCr 
value9, but also by the surgical therapies, such as the amount of fluids that are 
administered to the patient. In developing their AKI risk score, Jorge-Monjas et al. 
(2009) showed that postoperative SCr is positively correlated with subsequent AKI 
development. 
• lasix20 expresses the number of phials of a diuretic  administered during the first 24 
hours following surgery, each phial containing 20 mg. The reason for the inclusion of 
this variable is that it is believed that intraoperative and early postoperative variables 
impact the clinical course of the patient (see Jorge-Monjas et al. 2009) and, in turn, 
affect the postoperative treatments undertaken by clinicians. Administration of post-
operative diuretics usually takes place in case of excess fluid retention. Indeed, the 																																																								
9 Chapter 2 describes in more details the features of SC as a biomarker. 
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patient may be in a situation of fluid overload, due to the high volume of fluids that 
he/she has been administered during surgery. When this excess volume is very high, it 
might be threatening for the heart and the kidneys; therefore excretion of fluids is 
stimulated through diuretics. Moreover, in case the kidneys are not working properly, 
diuretics help kidney functions by means of stimulating excretion of fluids, therefore 
administration of diuretics might signal a higher risk of renal injury. 
• nc12h and nc12hcut03: these two variables refer to the results of the NephroCheck® 
Test, measured 12 hours after surgery. Therefore, they are available only for the 
second cohort of patients (year 2015). The first variable (nc12h) is continuous, while 
the other one (nc12hcut03) is a categorical variable that is defined according to the 
cut-off value already derived in previous studies (Ronco 2014). Recalling what 
explained in Chapter 2, the NephroCheck® Test delivers a number in a range between 
0.04 and 10.0 and a lower cut-off of 0.3 has been identified as it allows early 
recognition of most patients that are at risk of developing AKI within the following 12 
hours (see Kashani et al. 2013, and Hoste et al. 2014). The binary variable nc12hcut03 
is, thus, coded as 1 if the NephroCheck® Test delivers a value which is higher than 
0.3, it is coded as 0 in all the other cases. 
 
In the beginning, other variables were considered to be included in the model as 
covariates because they are considered risk factors for AKI: 
• nonelective: as explained before, in the 2014 cohort there are some patients who 
underwent urgency or emergency surgery procedures, which are likely to increase 
the risk of developing more adverse clinical conditions thereafter. For this group 
of patients, nonelective assumes the value of 1. The 2015 cohort, conversely, does 
not include any urgent/emergent patient by design. In the beginning nonelective 
was entered also in the multivariate model but then it was dropped, as explained in 
details further in this chapter. 
The following variables, differently from nonelective, were not significant in the 
univariate analysis (see paragraph 5.6) but were included in the multivariate model at the 
beginning of the analysis. They were excluded, later on, because non significant also in 
the multivariate model: 
• lactate: is the value of post-operative lactate. Jorge-Monjas et al. (2009) included 
lactate in their post-operative AKI risk score, so this variable was accounted for at 
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the beginning of this analysis. 
• clampdur is the duration (in minutes) of the aortic cross-clamping, a particular 
surgical procedure that may be harmful for kidneys, especially when prolonged. 
• diabetes: a dummy for the presence of diabetes, a disease which is a risk factor for 
AKI. 
• hypertens takes value 1 if the patient is affected by hypertension – another risk 
factor for AKI. 
• mv12h: a dummy that tells if the patient is still mechanically ventilated after 12h 
from surgery, it should signal that patient is recovering slowly as he/she is unable 
to breathe autonomously. 
• my, stands for myocardial infarction. If the patient had a myocardial infarction 
episode, this binary variable assumes value 1. Patients hospitalized with a 
myocardial infarction or that had a previous episode are at higher risk of 
developing AKI (Kosiborod 2012).   
 
5.4 DESCRIPTIVE STATISTICS 
The descriptive statistics of the variables listed above for the two study groups 
considered for the purpose of this dissertation are presented in Table 5.1. It can be noticed that 
some of these variables present missing values, thus leading to a reduction in the sample size 
for the estimation of the regression model.  
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Table 5.1 Descriptive Statistics 
	 2014	 2015	
Continuous	
Variables	
NON-AKI	 AKI	 NON-AKI	 AKI	
Mean±SD	 Obs	 Mean±	SD	 Obs	 Mean±	SD	 Obs	 Mean±SD	 Obs	
age	 64.74±12.38	 253	 72.38±9.02	 79	 59.37±12.73	 95	 66.93±11.01	 15	
eccdur	 109.69±37.83	 243	 120.67±51.0	 76	 118.67±33.8	 93	 148.77±59.16	 13	
postcrea	 .84±.201	 250	 1.10±.42	 79	 .77±.15	 92	 1.03±.29	 13	
lasix20	 1.35±2.07	 253	 4.92±7.23	 79	 .84±.97	 95	 2.03±4.13	 15	
lactate	 2.15±1.38	 246	 2.49±1.65	 76	 2.09±1.18	 91	 2.75±2.20	 13	
clampdur	 74.53±30.61	 230	 77.06±33.66	 69	 84.02±31.25	 92	 92.75±32.13	 12	
	 	 	 	 	 	 	 	 	 	
Categorical	
Variables	
NON-AKI	 AKI	 NON-AKI	 AKI	
n	 %	 n	 %	 n	 %	 n	 %	
akipre	 4	 1.58	 7	 8.86	 0	 0	 0	 0	
female	 79	 31.23	 27	 34.18	 28	 29.47	 4	 26.67	
obese	 32	 12.65	 23	 29.11	 9	 9.47	 5	 33.33	
nonelective	 46	 18.18	 23	 29.11	 0	 0	 0	 0	
ckdanamnesi	 10	 3.95	 9	 11.39	 0	 0	 0	 0	
svalve	 143	 56.52	 23	 29.11	 70	 73.68	 7	 46.47	
multvalve	 22	 8.7	 6	 7.59	 7	 7.37	 1	 6.67	
cabg	 73	 28.85	 42	 53.16	 8	 8.42	 4	 26.67	
aorta	 15	 5.23	 8	 10.13	 10	 10.53	 3	 20	
mv12h	 46	 18.18	 35	 44.30	 11	 11.58	 5	 33.33	
diabetes	 36	 14.23	 16	 20.25	 7	 7.37	 3	 20.00	
my	 33	 13.04	 14	 17.27	 1	 1.05	 0	 0	
hypertens	 177	 69.96	 63	 79.75	 53	 55.79	 11	 73.33	
 
To check whether  the two cohorts of patients – 2014, “no NephroCheck® Test cohort”, 
and 2015, the “NephroCheck® Test cohort” – were comparable and to assess if there existed 
any significant difference in the distribution of the selected covariates between the samples, a 
two sample t-test was run, for continuous variables, or a two sample test of proportions, for 
categorical variables. A t-test robust to unequal variance was run when equal variances could 
not be assumed. Results are presented in Table 5.2 (p-values in the last column).  
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Table 5.2 Patient population profile by cohort: 
2014 no- NephroCheck® Test and 2015 NephroCheck® Test 
Variable	
2014	 2015	
P	
Obs.	 Mean	 Std	Dev	 Obs.	 Mean	 Std	Dev	
age	 332	 66.55559	 12.10608	 110	 60.4	 12.72662	 0.0000	
eccdur	 319	 112.3072	 41.52865	 106	 122.3585	 38.72644	 0.0287	
postcrea	 329	 .9039514	 .2899141	 105	 .8047619	 .1925392	 0.0001	
lasix20	 332	 2.196551	 4.230015	 110	 1	 1.780372	 0.0000	
	 	 	 	 	 	 	 	
	 Obs	 n	 Mean	 Obs	 n	 Mean	 P	
akipost	 332	 79	 0.238	 110	 15	 0.136	 0.0240	
akipre	 332	 11	 0.033	 110	 0	 0	 0.0532	
female	 332	 106	 0.319	 110	 32	 0.291	 0.5779	
obese	 332	 55	 0.166	 110	 14	 0.127	 0.3363	
nonelective	 332	 69	 0.208	 110	 0	 0	 0.0000	
ckdanamnesi	 332	 19	 0.572	 110	 0	 0	 0.0103	
svalve	 332	 166	 0.50	 110	 77	 0.70	 0.0003	
multvalve	 332	 28	 0.843	 110	 8	 0.727	 0.6996	
cabg	 332	 115	 0.346	 110	 12	 0.109	 0.0000	
aorta	 332	 23	 6.93	 110	 13	 11.82	 0.1041	
P-values (two-sided) are obtained from two sample t-test, in case of continuous variables, and a 
two sample test of proportions, for categorical variables. 
 
There are, indeed, some variables that present statistically different (p-value<.05) – 
even if the difference is not dramatically large – averages between the two cohorts. On 
average, the 2014 cohort is older, undergoes surgical procedures that tend to last less, shows 
higher values of postoperative creatinine (postcrea) and is administered more diuretics 
(lasix20) in the early post-surgical period. As far as the difference in administration of 
diuretics is concerned, it is worth reminding that the variable lasix20 is expressed in terms of 
number of phials administered to the patient; from a clinical point of view, a difference of one 
phial is not substantial. Moreover, within the 2014 cohort, a higher proportion of patients 
underwent CABG procedures or was already affected by CKD (stage 3 or 4) at the moment of 
hospitalization.  
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At this point it is important to recall what has been briefly explained in the previous 
paragraphs, concerning the selection of the two samples and how this might influence patient 
population profile. Differently from the no-NephroCheck® Test cohort (2014), the 
NephroCheck® Test group (2015) does not include patients that underwent urgency or 
emergency surgery. This not only affects the distribution of the variable nonelective, which is 
by definition 0 for all the NephroCheck® Test cohort individuals, but also other features. 
Among the 2014 cohort, there are some patients showing a higher risk profile, from a medical 
point of view, just because their clinical conditions at the moment of surgery are urgent. For 
example, this might explain why, in this cohort, there is a significantly higher proportion of 
patients that develop AKI after surgery (akipost) and more CABG cases (cabg), a surgical 
procedure that is common in urgency cases. 
Basically, these findings suggest that some differences exist between the two cohorts, as 
far as the distribution of the covariates of interest is concerned, and this could interfere with 
the aim of the study – estimating the ability of the NephroCheck® Test in predicting the 
probability of developing AKI after cardiac surgery. Indeed, in estimating the effect of the 
NephroCheck® Test on the 2015 cohort, we might find a result that is actually due to 
underlying existing differences between the two cohorts, if these variables correlate with the 
outcome akipost. However, this issue is addressed by means of controlling for these 
confounders in the multiple regression model, illustrated in the following paragraphs, thus 
estimating the effect of the NephroCheck® Test other things being equal. 
 
5.5 MODEL ESTIMATION AND ESTIMATION RESULTS 
Recalling the equations described in Chapter 3, the model to be estimated is a multiple 
logistic regression model:  𝑌 = 𝜋 𝒙 + 𝜀 
where the probability 𝜋 𝒙  is expressed as 𝜋 𝒙 = 𝑒! 𝒙1+ 𝑒! 𝒙  
and 𝑔 𝒙  is the logit transformation 𝑔 𝒙 = ln 𝜋 𝒙1− 𝜋 𝒙 = 𝛽! + 𝛽!𝑥! + 𝛽!𝑥! +⋯+ 𝛽!𝑥!. 10 																																																								
10 See Chapter 3 for the theoretical framework on multiple logistic regression models. 
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The vector of parameters 𝜷! = (𝛽!,𝛽!,… ,𝛽!) is estimated through the method of maximum 
likelihood, by means of maximizing the log-likelihood function 𝐿 𝜷 = ln 𝑙 𝜷 = 𝑦!ln [𝜋 𝒙! ]+ 1− 𝑦! ln [1− 𝜋 𝒙! ]!!!! . 
In order to identify the covariates to include in the multivariable logistic regression 
model, the method of purposeful selection of covariates has been applied, as described by 
Hosmer, Lemeshaw and Sturdivant (2013). In the beginning, a wide group of variables of 
interest was selected because they were thought to be risk factors or to correlate with AKI 
after cardiac surgery, according the literature and/or physicians’ experience. The association 
of these potential predictors with the outcome was analysed through univariate logistic 
regression: regression coefficients, p-values and odds ratio were computed. 
The odds ratio (OR) for a dichotomous predictor 𝑥! is defined as  
OR = 𝜋 11− 𝜋 1𝜋 01− 𝜋 0 = 𝑒!! 
and it represents the odds that the outcome is present (𝑦 = 1), given that 𝑥! = 1, as compared 
to the odds that the outcome occurs in case 𝑥! = 0. For continuous predictors, the odds-ratio 
is defined for a specified change “c” in the covariate, while for categorical predictors it is 
calculated with respect to the reference group. 
In the beginning, a multiple regression model was fit with all the predictors described in 
paragraph 5.3. Table 5.3 displays results from univariate logistic regressions only for the 
covariates that were statistically significant in the univariate analysis and were selected to fit a 
successive multivariate model. The other variables described in the previous paragraph were 
not statistically significant either in univariate and multivariate analysis, so they were not 
further considered in the model.  
 
  
	60	
Table 5.3. Univariate Logit Regressions 
akipost	 Coeff	 Std.	Err.	 z	 P>z	 [95%	Conf.	Interval]	 Odds	Ratio	
	
akipre	 1.800403	 .6409072	 2.81	 0.005	 .5442474	 3.056558	 6.052083	
_cons	 -1.240787	 .1338094	 -9.27	 0.000	 -1.503048	 -.9785252	 .2891566	
	
female	 .1342006	 .2732639	 0.49	 0.623	 -.4013868	 .669788	 1.143622	
_cons	 -1.207812	 .158044	 -7.64	 0.000	 -1.517572	 -.8980511	 .2988506	
	
obese	 1.042569	 .3116252	 3.35	 0.001	 .4317952	 1.653344	 2.836496	
_cons	 -1.372811	 .1496062	 -9.18	 0.000	 -1.666034	 -1.079588	 .2533937	
	
nonelective	 .61422	 .2964885	 2.07	 0.038	 .0331131	 1.195327	 1.848214	
_cons	 -1.307367	 .1506256	 -8.68	 0.000	 -1.602588	 -1.012146	 .2705314	
	
ckdanamnesi	 1.139206	 .4790742	 2.38	 0.017	 .2002376	 2.078174	 3.124286	
_cons	 -1.244566	 .1356501	 -9.17	 0.000	 -1.510435	 -.978697	 .2880658	
	
surtype	 	 	 	 	 	 	 	
1	 1.695652	 .8689162	 1.03	 0.303	 .621082	 4.629399	 1.695652	
2	 3.577129	 1.061024	 4.30	 0.000	 2.000124	 6.397529	 3.577129	
3	 3.315942	 1.631693	 2.44	 0.015	 1.264014	 8.698854	 3.315942	
_cons	 .1608392	 .0361338	 -8.13	 0.000	 .1035529	 .2498165	 .1608392	
	
agecut2	 	 	 	 	 	 	 	
65-	 .9519779	 .3620571	 2.63	 0.009	 .242359	 1.661597	 2.590829	
75-	 1.674355	 .3505258	 4.78	 0.000	 .9873368	 2.361373	 5.335351	
_cons	 -2.08833	 .283334	 -7.37	 0.000	 -2.643655	 -1.533006	 .1238938	
	
eccdur	 .0060719	 .0030491	 1.99	 0.046	 .0000956	 .0120481	 1.00609	
_cons	 -1.860188	 .3816048	 -4.87	 0.000	 -2.608119	 -1.112256	 .1556434	
	
postcrea	 3.44328	 .5897006	 5.84	 0.000	 2.287488	 4.599072	 31.28941	
_cons	 -4.392156	 .5820989	 -7.55	 0.000	 -5.533049	 -3.251263	 .012374	
	
lasix20	 .2695997	 .064497	 4.18	 0.000	 .1431878	 .3960116	 1.30944	
_cons	 -1.755123	 .1828338	 -9.60	 0.000	 -2.113471	 -1.396776	 .1728859	
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In Table 5.4 are displayed the estimated results from the multiple logistic regression 
model on the cohort of 2014 – no NephroCheck® Test - including all the covariates present in 
Table 5.3. 
 
Table 5.4. Logit Regression (1) 
Logit	Regression	 Number	of	obs	=	316	
LR	chi2(12)	=	107.73	
Prob	>	chi2	=	0.0000	
Log	likelihood	=	-120.4593	 Pseudo	R2	=	0.3090	
	
akipost	 Coeff.	 Std.	Err.	 z	 P>z	 [95%	Conf.	Interval]	
	 	 	 	 	 	 	
akipre	 .7007932	 .7985516	 0.88	 0.380	 -.8643391	 2.265926	
female	 .811344	 .3872266	 2.10	 0.036	 .0523937	 1.570294	
agecut2	 	 	 	 	 	 	
65-	 .7084455	 .4342146	 1.63	 0.103	 -.1425995	 1.55949	
75-	 1.245737	 .4352451	 2.86	 0.004	 .3926721	 2.098802	
nonelective	 .264335	 .405631	 0.65	 0.515	 -.5306872	 1.059357	
ckdanamnesi	 -1.380507	 .8135363	 -1.70	 0.090	 -2.975009	 .2139944	
obese	 .9229286	 .4019929	 2.30	 0.022	 .135037	 1.71082	
eccdur	 .0000795	 .0041153	 0.02	 0.985	 -.0079863	 .0081453	
surtype	 	 	 	 	 	 	
1	multvalve	 .2055498	 .6978997	 0.29	 0.768	 -1.162308	 1.573408	
2	cabg	 1.437388	 .3961625	 3.63	 0.000	 .6609241	 2.213852	
3	aorta	 1.33304	 .6573812	 2.03	 0.043	 .0445966	 2.621483	
postcrea	 3.239962	 .7773735	 4.17	 0.000	 1.716338	 4.763586	
lasix20	 .1996874	 .0647919	 3.08	 0.002	 .0726976	 .3266771	
_cons	 -6.425256	 .9638716	 -6.67	 0.0000	 -8.314409	 -4.536102	
 
After fitting a multiple regression model containing the identified potential predictors, 
some turned out to be statistically not significant in the multivariable model; therefore it was 
considered whether dropping these variables from the model. 
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In particular, some of the findings presented in the table above were different from what 
could be expected, based on the literature. For example, the duration of ECC (eccdur) turns 
out to be not significant at all. However, this could partially be explained by the fact that this 
sample cohort includes a lot of valve surgical procedures (svalve and multivalve categories of 
surtype). Specifically, at the San Bortolo Hospital, most of these valve surgeries are 
performed through the so-called minimally invasive procedure, which involves tiny incisions 
and should lead to a quicker and less discomfort patient’s recovery. Indeed, these types of 
surgery are usually not as dangerous for the kidney as a CABG procedure (cabg) and tend to 
last less. Secondly, many of the studies conducted so far with the aim of studying and 
identifying the risk factors of AKI after cardiac surgery have considered CABG patients only. 
These patients are characterized by a reduced heart function that, in turn, affects negatively 
the kidneys in the sense that kidneys suffer from reduced blood pumping and the risk of AKI 
increases. Therefore it is reasonable to assume that the duration of ECC may be a particularly 
relevant factor in this subpopulation.  
Also the effect of a preoperative AKI event is not significant in this sample (akipre), 
which might be due to the fact that a very small proportion of patients (3.31%) reported this 
feature. These covariates were retained in the multivariable model, even if statistically not 
significant according to the p-value of their Wald statistic, because they improved the model 
goodness of fit and/or because of their importance from a clinical viewpoint. In particular, 
akipre was deemed necessary in the multiple regression model for clinical reasons: an 
individual who experiences AKI before surgery is, in fact, more susceptible to further insults 
to the kidney. 
On the contrary, it was considered whether nonelective could be dropped. A likelihood 
ratio test was computed before taking the final decision. The test is performed by means of 
calculating the likelihood ratio: 𝑙𝑟 = −2 ln 𝐿 𝑚!𝐿 𝑚!  
where 𝐿(𝑚!), 𝐿(𝑚!) are the likelihood of the more restrictive and less restrictive model, 
respectively. Under the null hypothesis the resulting statistic follows a chi-squared 
distribution, with degrees of freedom corresponding to the number of parameters that are 
constrained.  
Results from the multiple logistic regression model, excluding nonelective from the 
covariates, are presented in Table 5.5.  
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Table 5.5. Logit Regression (2) 
Logit	Regression	 Number	of	obs	=	316	
LR	chi2(12)	=	107.31	
Prob	>	chi2	=	0.0000	
Log	likelihood	=	-120.66996	 Pseudo	R2	=	0.3078	
	
akipost	 Coeff.	 Std.	Err.	 z	 P>z	 [95%	Conf.	Interval]	
	 	 	 	 	 	 	
akipre	 .7257285	 .8008885	 0.91	 0.365	 -.843984	 2.295441	
female	 .7806902	 .3843724	 2.03	 0.042	 .0273341	 1.534046	
agecut2	 	 	 	 	 	 	
65-	 .7234092	 .4338026	 1.67	 0.095	 -.1268284	 1.573647	
75-	 1.255784	 .4355459	 2.88	 0.004	 .4021301	 2.109438	
ckdanamnesi	 -1.328244	 .8052198	 -1.65	 0.099	 -2.906446	 .2499578	
obese	 .894472	 .3993891	 2.24	 0.025	 .1116838	 1.67726	
eccdur	 -.0001824	 .0041145	 -0.04	 0.965	 -.0082467	 .007882	
surtype	 	 	 	 	 	 	
1	multvalve	 .1726546	 .6958329	 0.25	 0.804	 -1.191153	 1.536462	
2	cabg	 1.504977	 .3818915	 3.94	 0.000	 .756483	 2.25347	
3	aorta	 1.373589	 .6523991	 2.11	 0.035	 .0949103	 2.652268	
postcrea	 3.232229	 .7758255	 4.17	 0.000	 1.711639	 4.752819	
lasix20	 .1961158	 .0641255	 3.06	 0.002	 .0704321	 .3217995	
_cons	 -6.425256	 .9638716	 -6.67	 0.000	 -8.314409	 -4.536102	
 
 
The likelihood ratio test delivers a statistic of 0.42, which is distributed as a chi-squared 
with one degree of freedom. This corresponds to a p-value of 0.5163, therefore model (2) was 
chosen as the base model for further analysis. It is important to underline, once more, that this 
model still controls for all the relevant and statistically significant covariates that are 
distributed differently between the two cohorts, as showed in previous Table 5.2. 
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5.6 ASSESSING THE GOODNESS OF FIT OF THE MODEL 
Hereafter are presented some regression diagnostics, performed with the aim of 
checking that model (2) fits sufficiently well, before applying it to the 2015 cohort. 
Goodness of fit was, first of all, assessed by means of computing the Hosmer-
Lemeshaw statistic, splitting the sample into 10 groups of covariate patterns according to the 
strategy suggested by Hosmer, Lemeshaw and Sturdivant (2013). The statistic is 6.61 and the 
associated p-value is 0.5790, which indicates that the model fits sufficiently well.  
Secondly, it was necessary to ensure that no important variables have been omitted from 
the model and that the correct link function (namely, the logit function) has been chosen. 
Consequently, an additional regression was run, where the explanatory variables were the 
linear predicted values from the original model (_hat) and their squares (_hatsq). This 
strategy allows detecting a specification error because, if the variable _hatsq is found to be 
statistically significant, it means that the model is not properly specified. On the contrary, if 
the model is correctly specified, _hat is significant while _hatsq should not have much 
predictive power except by chance. Results from this test for specification error are displayed 
in Table 5.6. 
 
Table 5.6 Specification Error Test – Logit Regression (2) 
Specification	Error	Test	 Number	of	obs	=	316	
LR	chi2(2		=	108.60	
Prob	>	chi2	=	0.0000	
Log	likelihood	=	-120.02563	 Pseudo	R2	=	0.3115	
	
akipost	 Coef.	 Std.	Err.	 z	 P>z	 [95%	Conf.	Interval]	
_hat	 .9308983	 .1256512	 7.41	 0.000	 .6846265	 1.17717	
_hatsq	 -.0569775	 .038459	 -1.48	 0.138	 -.1323557	 .0184007	
_cons	 .0719111	 .2107614	 0.34	 0.733	 -.3411737	 .4849959	
 
The variable _hat is statistically significant, which confirms that the relevant predictors 
have been included in the model, and _hatsq is not significant (p-value=0.138), so according 
to the test we are not in the presence of a specification error. 
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The results of the fitted regression model and, in particular, its performance in terms of 
classification can be then assessed by means of constructing a classification table. This 
approach uses the estimated probability to predict group membership and, in particular, a 
classification table shows the results deriving from cross-classifying the observed values and 
the predicted values for the outcome variable. In this way, it is possible to compare the actual 
number of events with the number of events predicted by the logistic regression model. To 
construct this table, it is necessary to define a cut-point and the estimated probability must be 
compared to it: if the estimated probability is higher than this specified cut-off, then the 
predicted value is classified as positive (in this context, AKI); if the is lower than the cut-off, 
it is classified as negative (non-AKI). Therefore, accurate prediction of group membership 
provides evidence that the model fits (see Hosmer, Lemeshaw and Sturdivant 2013). 
 
In Figure 5.1, sensitivity and specificity are plotted against all possible probability cut-
off points. This kind of graphical representation is useful in order to decide an “optimal” 
probability cut-off for the purpose of classification. This choice depends also on the objective 
of classification, such as minimizing the false positives, maximizing the proportion of cases 
correctly classified, maximizing the negative predictive value and so on. However, according 
to this plot, an “optimal” choice for a cut-off point could be 0.25, where the sensitivity and 
the specificity curves approximately cross. Table 5.7 reports the classification table and other 
summary statistics at the cut-off value of 0.25.  
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Figure 5.1. Logit Model (2)
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Table 5.7 Classification Table at 25%. 
2014 cohort 
	 Actual	 	
Classified	 AKI	 non-AKI	 Total	
AKI	 59	 49	 108	
non-AKI	 17	 191	 208	
Total	 76	 240	 316	
	 	 	 	
Sensitivity	 77.63%	 	
Specificity	 79.58%	 	
PPV	 54.63%	 	
NPV	 91.83%	 	
Correctly	classified	 79.11%	 AUC	85.85%	
	
 
 
The Receiver Operating Characteristic (ROC) curve is also informative about the ability 
of the model to discriminate between subjects that develop and do not develop the disease.  
Figure 5.2 shows the ROC curve for logit model (2), where sensitivity is plotted in function of 
1-specificity for each cut-off value. The area under the ROC curve is 85.85%, which suggests 
that the model performs relatively well in discriminating between AKI and non-AKI patients. 
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5.7 ESTIMATING THE EFFECT OF THE NEPHROCHECK® TEST 
After assessing the model’s goodness of fit and finding no evidence of model’s 
misspecification, the same model was applied on the 2015 cohort, at first without including 
the results of the NephroCheck® Test as a covariate (model 3), then a separate regression was 
run to assess the improvements in prediction arising from the inclusion of the NephroCheck® 
Test variable to the base model (model 4).  
 
Table 5.8. Logit Regression (3) 
Logit	Regression	 Number	of	obs	=	105	
LR	chi2(12)	=	32.23	
Prob	>	chi2	=	0.0000	
Log	likelihood	=	-23.202789	 Pseudo	R2	=	0.4099	
	
akipost	 Coeff.	 Std.	Err.	 z	 P>z	 [95%	Conf.	Interval]	
	 	 	 	 	 	 	
akipre	 (omitted)	 	 	 	 	 	
female	 1.811228	 1.252554	 1.45	 0.148	 -.6437317	 4.266189	
agecut2	 	 	 	 	 	 	
65-	 .3003301	 .9742612	 0.31	 0.758	 -1.609187	 2.209847	
75-	 .9525558	 1.245209	 0.76	 0.444	 -1.48801	 3.393121	
ckdanamnesi	 0	 (omitted)	 	 	 	 	
obese	 -.2083682	 1.220265	 -0.17	 0.864	 -2.600043	 2.183307	
eccdur	 .0202696	 .0100347	 2.02	 0.043	 .0006019	 .0399374	
surtype	 	 	 	 	 	 	
1	multvalve	 -.5377587	 1.501564	 -0.36	 0.720	 -3.480769	 2.405252	
2	cabg	 .8253511	 1.053822	 0.78	 0.434	 -1.240103	 2.890805	
3	aorta	 -.9411625	 1.379194	 -0.68	 0.495	 -3.644333	 1.762008	
postcrea	 9.48359	 3.682992	 2.57	 0.010	 2.265058	 16.70212	
lasix20	 .3802842	 .4347449	 0.87	 0.382	 -.4718002	 1.232369	
_cons	 -14.0992	 4.091784	 -3.45	 0.001	 -22.11895	 -6.079455	
 
	68	
Since the two cohorts presented some differences as far as the distribution of the 
variables of interest is concerned, a test on the equality of regression coefficients was run.  
It consists of a cross-model hypotheses testing: a Wald test to assess whether the effect of 𝑥!, 𝑥!,… , 𝑥! on the binary outcome is the same across two models – in this setting, model (2) 
and (3) – that are fit on independent samples, so that the estimators are stochastically 
independent. 
Let the estimated coefficient vector be b and its estimated variance-covariance matrix be V. 
Let 𝜷 be the true value of the parameter and R 𝜷 =r the set of p linear hypotheses to be tested 
jointly, then the Wald test statistic is 𝑊 = (𝐑 𝒃 − 𝐫)′ 𝐑𝐕𝐑′ !!(𝐑 𝒃 − 𝐫), 
which under the null hypothesis follows a chi-squared distribution with p degrees of freedom. 
More specifically, the hypotheses to be tested in this case is the equality of coefficients across 
the model fit on the 2014 sample and on the 2015 sample: 𝐻!:𝒃!"#$ = 𝒃!"#$ 
and the Wald statistic is then 𝑊 = (𝒃!"#$ − 𝒃!"#$)′ Var 𝒃!"#$ + Var 𝒃!"#$ !!(𝒃!"#$ − 𝒃!"#$), 
where Var .  is the estimated variance-covariance matrix for the coefficients. 
Hypotheses testing delivers a Wald statistic of 𝑊 = 14.87, which under the null hypothesis is 
a value from a chi-squared with 10 degrees of freedom (cons excluded). With a p-value of 
0.1368 the null hypothesis that the coefficients across the two models are the same cannot be 
rejected. 
Given this result, the following step consisted of adding to the model the covariate 
containing the results of the NephroCheck® Test. First of all, the binary coding of the 
NephroCheck® Test variable was considered (nc12hcut03) and results of the regression model 
are shown in Table 5.9.  
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Table 5.9. Logit Regression (4) 
Logit	Regression	 Number	of	obs	=	105	
LR	chi2(12)	=	39.21	
Prob	>	chi		=	0.0000	
Log	likelihood	=	-19.712646	 Pseudo	R2	=	0.4986	
	
akipost	 Coeff.	 Std.	Err.	 z	 P>z	 [95%	Conf.	Interval]	
	 	 	 	 	 	 	
akipre	 (omitted)	 	 	 	 	 	
female	 1.513295	 1.24011	 1.22	 0.222	 -.9172759	 3.943866	
agecut2	 	 	 	 	 	 	
65-	 -.5566859	 1.104002	 -0.50	 0.614	 -2.72049	 1.607119	
75-	 .8689912	 1.382606	 0.63	 0.530	 -1.840866	 3.578848	
ckdanamnesi	 (omitted)	 	 	 	 	 	
obese	 -1.21116	 1.465763	 -0.83	 0.409	 -4.084002	 1.661683	
eccdur	 .0314445	 .0135114	 2.33	 0.020	 .0049627	 .0579263	
surtype	 	 	 	 	 	 	
1	multvalve	 -1.094783	 1.538816	 -0.71	 0.477	 -4.110806	 1.921241	
2	cabg	 .4871458	 1.182684	 0.41	 0.680	 -1.830872	 2.805164	
3	aorta	 -1.592183	 1.571634	 -1.01	 0.311	 -4.672529	 1.488163	
postcrea	 11.96972	 4.54354	 2.63	 0.008	 3.064548	 20.8749	
lasix20	 .6151161	 .515955	 1.19	 0.233	 -.3961372	 1.626369	
nc12hcut03	 2.967106	 1.204397	 2.46	 0.014	 .6065308	 5.32768	
_cons	 -18.18748	 5.402325	 -3.37	 0.001	 -28.77584	 -7.599119	
 
As expected, the coefficient of nc12hcut03 is positive and statistically significant (p-
value 0.014). However, the most interesting and important results can be better understood by 
comparing the two models (with and without nc12hcut03) applied on the same cohort of 
patients, in particular by looking at the respective classification tables. This helps better 
understanding how the NephroCheck® Test improves the performance of the model in 
discriminating patients who will develop AKI after cardiac surgery from those who will not. 
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Table 5.10. Classification Table at 25%. 
Without NephroCheck® Test – 2015 cohort 
 Table 5.11. Classification Table at 25%. 
With NephroCheck® Test (nc12hcut03)  
– 2015 cohort 
Classified	
Actual	
Total	
	
Classified	
Actual	
Total	
AKI	 non-AKI	 	 AKI	 non-AKI	
AKI	 9	 6	 15	 	 AKI	 11	 6	 17	
non-AKI	 4	 86	 90	 	 non-AKI	 2	 86	 88	
Total	 13	 92	 105	 	 Total	 13	 92	 105	
	 	 	
Sensitivity	 69.23%	 	 	 	 Sensitivity	 84.62%	 	 	
Specificity	 93.48%	 	 	 	 Specificity	 93.48%	 	 	
PPV	 60.00%	 	 	 	 PPV	 64.71%	 	 	
NPV	 95.56%	 	 	 	 NPV	 97.73%	 	 	
Correctly	classified	90.48%	 AUC		87.54%	 	 Correctly	classified	92.38%	 AUC		92.38%	
 
The model without nc12hcut03 already did a relatively good job at classifying the 
patients into AKI and non-AKI groups (90.48% of patients correctly classified); however, 
once nc12hcut03 is included, the model improves substantially in terms of sensitivity (from 
69.23% to 84.62%) without losing anything in terms of specificity. In other words, the true 
positives rate increases and, at the same time, the false negative rate decreases.  
 
Figure 5.3 also displays the improvement in the area under the ROC curve, due to the 
inclusion of nc12hcut03 in the model.  
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Afterwards, the continuous variable nc12h replaced nc12hcut03 in the logit model and 
the two models were compared. Results from this regression are displayed in Table 5.12 
below. 
  
Model (3) - with NephroCheck
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Figure 5.3. ROC curves - 2015 cohort
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Table 5.12. Logit Regression (5) 
Logit	Regression	 Number	of	obs	=	105	
LR	chi2(12)	=	36.95	
Prob	>	chi2	=	0.0001	
Log	likelihood	=	-20.840295	 Pseudo	R2	=	0.4699	
	
akipost	 Coeff.	 Std.	Err.	 z	 P>z	 [95%	Conf.	Interval]	
	 	 	 	 	 	 	
akipre	 (omitted)	 	 	 	 	 	
female	 2.201251	 1.357064	 1.62	 0.105	 -.4585449	 4.861047	
agecut	 	 	 	 	 	 	
65-	 -.2109562	 1.095458	 -0.19	 0.847	 -2.358015	 1.936103	
75-	 .8274323	 1.351367	 0.61	 0.540	 -1.821198	 3.476062	
ckdanamnesi	 (omitted)	 	 	 	 	 	
obese	 -.8781113	 1.459336	 -0.60	 0.547	 -3.738356	 1.982134	
eccdur	 .024244	 .0120807	 2.01	 0.045	 .0005663	 .0479217	
surtype	 	 	 	 	 	 	
1	multvalve	 -.6103087	 1.544984	 -0.40	 0.693	 -3.638423	 2.417805	
2	cabg	 .15481	 1.205525	 0.13	 0.898	 -2.207976	 2.517596	
3	aorta	 -1.321832	 1.514433	 -0.87	 0.383	 -4.290066	 1.646402	
postcrea	 11.73584	 4.51603	 2.60	 0.009	 2.884579	 20.58709	
lasix20	 .7005834	 .4972069	 1.41	 0.159	 -.2739241	 1.675091	
nc12h	 4.161741	 1.853187	 2.25	 0.025	 .5295625	 7.79392	
_cons	 -17.52182	 5.320362	 -3.29	 0.001	 -27.94954	 -7.094101	
 
Also the continuous variable nc12h is statistically significant and results in terms of 
coefficient value and significance of the whole model do not seem to differ a lot. In terms of 
classification performance at 25% probability cut-off, Table 5.13 shows that the model with 
the continuous variable nc12h is less sensitive (76.92%, as compared to 84.62% of the model 
with the binary variable nc12hcut03) and the false number of false negatives slightly 
increases, but the false positive rate decreases (specificity increases to 95.65%, as compared 
93.48%). Overall, the proportion of patients correctly classified mildly increases to 93.33%. 
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Table 5.13. Classification Table at 25%. 
With NephroCheck® Test (nc12h) 
– 2015 cohort 
	 Actual	 	
Classified	 AKI	 non-AKI	 Total	
AKI	 10	 4	 14	
non-AKI	 3	 88	 91	
Total	 13	 92	 105	
	 	 	 	
Sensitivity	 76.92%	 	
Specificity	 95.65%	 	
PPV	 71.43%	 	
NPV	 96.70%	 	
Correctly	classified	 93.33%	 AUC	89.63%	
 
A criterion that can be used in order to decide between the two alternative model 
specifications is the Akaike Information Criterion (AIC) (Hosmer, Lemeshaw and Sturdivant 
2013). This measure is defined in the following way: AIC = −2×𝐿 + 2×(𝑝 + 1), 
where L is the log-likelihood of the fitted model and p is the number of regression coefficients 
excluding constant covariates. The rule is, in general, that models with a lower value of AIC 
should be preferred with respect to models with a higher value.  
In this context, model (4) has an AIC=63.425 and model (5) reports AIC=65.681. Difference 
in AIC is not substantial, however, according to this criterion the model with the binary 
variable nc12hcut03 may be preferred to the model with the continuous one, nc12h. 
 
Even if these results mildly support the choice of the binary variable nc12hcut03, 
additional analysis could be done to check whether the variable nc12h is linear in the logit, by 
means of fitting a lowess smooth curve. 
 “Lowess” stands for locally weighted regression and lowess smoothing is a non-
parametric procedure that provides a graphical representation of the relationship between the 
outcome variable and one (or more) independent variable (Jacoby 2000). This technique 
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consists of fitting a regression line to the data around an observation i (𝑥! ,𝑦!) and, from this 
regression of 𝑦 on 𝑥, predict the smoothed value 𝑦! for that particular point. This regression is 
“local” in the sense that only the subset of observations falling close to observation i (along 
the 𝑥 axis) are used to predict the smoothed value. The weighting procedure is such that the 
central point (𝑥! ,𝑦!) receives the highest weight, while points that are farther receive less 
weight. The procedure is repeated for each observation (a separate regression equation is 
estimated for each i) to draw the plot of the locally weighted regression, by means of 
connecting adjacent fitted points. 
 
Figure 5.5 shows the lowess smoothed curve in terms of the log of the odds ratio and it 
actually shows some departure from a linear relationship. 
However, this issue can be further examined through Fractional Polynomials modelling. 
This method can be used when there is suspect of non-linear relationship between the 
outcome and a continuous predictor, nc12h in this setting, in ordee to identify the optimum 
power transformation for the predictor. A fractional polynomial model is fit choosing powers 
from the subset 𝑆 = −2,−1,−0.5, 0, 0.5, 1, 2, 3  and allowing for logarithms, then 
substituting the continuous covariate with the best fitting fractional polynomial, defined as  
𝛽! + 𝛽!𝐻!(𝑥)!!!!  
where 𝐻!(𝑥) = 𝑥(!!) and for 𝑗 = 2,… ,𝑚: 
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Figure 5.5. Lowess Smoother
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𝐻! 𝑥 = 𝑥(!!)                  if 𝑝! ≠ 𝑝!!!𝐻!!! 𝑥  ln 𝑥  if 𝑝! = 𝑝!!!. 
The “best” model is the one with the lowest deviance, m=2 in Table 5.14, which is then 
compared to lower degree models through partial F test. The column of p-values shows that 
the linear model cannot be rejected in favour of the fractional polynomial model with m=2 (p-
value=0.172), meaning that there is no need for adding power transformations of the covariate 
nc12h to the model. 
 
Table 5.14. Fractional Polynomial Analysis of nc12h 
nc12h	 df	 Deviance	 Dev.	dif.	 P	 Powers	
	 	 	 	 	 	
Not	in	model	 0	 46.406	 9.718	 0.045	 	
Linear	 1	 41.681	 4.993	 0.172	 1	
m	=	1	 2	 37.421	 0.733	 0.693	 -.5	
m	=	2	 4	 36.688	 --	 --	 -2	-2	
 
 
Overall, the comparison of models (4) and (5) can lead to the conclusion that the two 
models do not exhibit substantial differences and the choice between the two model could be 
based on the objective of classification (such minimization of the false positive rate or 
minimization of the false negative rate). Moreover, according to Fractional Polynomials 
analysis, it can be concluded that the relationship between the continuous covariate of interest 
(nc12h) and the outcome does not show substantial departures from linearity, thus suggesting 
that there is no need for adding other additional terms to the model. 
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CONCLUSIONS 
This dissertation has investigated the use of the NephroCheck® Test as a diagnostic tool 
for the early identification of AKI (Acute Kidney Injury). AKI is a relevant complication 
affecting hospitalized patients and it is particularly frequent after cardiac surgery and in 
intensive care units. Any AKI case, from its milder forms to the most severe ones, is 
associated with adverse clinical outcome, such as increased morbidity and mortality, longer 
hospital stay, need for additional treatments including renal replacement therapy (RRT). 
These negative impacts are not limited to the hospitalization period but might extend, 
especially in more severe cases, over a long run. As a result, AKI is associated with a 
substantial increase in health care cost. Kerr et al. (2014) estimated that the annual AKI-
associated costs, including inpatient care and post-discharge care, is around £1.2 billions in 
England and represents 1% of the National Health System budget. Besides that, AKI is likely 
to have adverse long-term clinical effects, even when patients recover renal function. Pannu et 
al. (2013) found that, among the patients who had developed AKI (KDIGO stage 2 or 3), 
30.8% of them died and 2.1% progressed to kidney failure (CKD stage 5) requiring dialysis 
within a 34-month period. 
Unfortunately, there is no specific therapy for AKI but several clinical measures can be 
adopted to avoid progression of the injury and patients with a high risk of developing AKI 
can be monitored and treated carefully to prevent AKI. This means that the primary goal for 
dealing effectively with AKI is to recognise the onset of the injury early, in order to allow 
timely identification of appropriate treatments and interventions. An entire branch of research, 
based on this principle, has been directed towards the discovery and validation of early 
biomarkers for the diagnosis of AKI. Many biomarkers have actually been investigated and a 
combination of two of them has provided the best performance, so far: urine insulin-like 
growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 
(TIMP-2). The NephroCheck® Test (Astute Medical, San Diego, CA, USA) is a diagnostic 
device that has been developed to allow measurement of the concentration of these two 
markers and, eventually, support AKI detection. 
The NephroCheck® Test was employed on a cohort of patients undergoing cardiac 
surgery in the San Bortolo Hospital of Vicenza during 2015. The results of testing were 
available for an empirical evaluation of the performance of the NephroCheck® Test as a 
diagnostic method for detecting AKI early. The basic idea consisted of comparing a method 
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for AKI recognition, based on information available in the clinical routine (thus, without 
additional examinations and costs), to one that accounted for the results provided by the 
NephroCheck® Test.  
To do so, a multiple logistic regression model for predicting the probability that a 
patient develops AKI after cardiac surgery was constructed on a sample of patients who 
underwent cardiac surgery in 2014. The individuals in the two samples (2014-no 
NephroCheck® Test and 2015-NephroCheck® Test) had comparable epidemiological and 
clinical characteristics. The multiple regression model included variables describing patients’ 
clinical background, surgical procedures and early post-surgical features; the covariates of the 
model were selected based on clinical considerations as well as goodness of fit of the logistic 
model. The selected model was then applied to the 2015 cohort and, subsequently, the results 
of the NephroCheck® Test were included as a covariate, in order to assess improvement in 
AKI risk prediction through the model. 
Findings can be summarized as follows. The NephroCheck® Test is statistically 
significant as a covariate in the multiple logistic regression model (p-value < 0.05) and an 
increase in test results signals a higher probability of developing AKI after cardiac surgery, 
ceteris paribus. Once the NephroCheck® Test is included, the performance of the model 
improves: the area under the curve (AUC) goes from 87.54% to 92.38%, which is a very 
positive result, and the main contribution is given in terms of sensitivity (increasing from 
69.23% to 84.62%, at the selected probability cut-off of 25%). 
The test is structured in a way that it provides a numerical result over a continuous 
scale, with higher numbers indicating an increasing risk of developing AKI. Previously 
published validation studies had identified a 0.3 cut-off value for the test result as a threshold 
(see Ronco 2014), such that patients with test values higher than 0.3 are identified as having 
an increased risk of developing moderate to severe AKI (KDIGO stages 2-3). In the present 
study, the NephroCheck® Test was evaluated for predicting the probability of developing AKI 
(any stage) according to KDIGO guidelines. A binary covariate assuming value 1 for 
NephroCheck® Test results higher than 0.3 as well as a continuous covariate were generated 
and considered in two separate models. Comparing the two models, no substantial difference 
emerged in terms of overall model performance for the classification of patients into AKI and 
non-AKI groups. Additionally, no significant discontinuities or need for adding power 
transformations of the continuous NephroCheck® Test covariate were found. 
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The results presented in this dissertation must be evaluated in light of some 
considerations. First of all, the NephroCheck® Test was employed on a specific and rather 
homogeneous population, namely that of patients undergoing cardiac surgery. Therefore, 
further research would be necessary to validate the use of the test on a more heterogeneous 
population, such as including critical care patients. 
Analysis and comparison of the classification tables of the models described here show 
that the NephroCheck® Test improves early AKI detection with respect to a model that 
accounts only for other clinical parameters. Nevertheless, an integrated approach could 
probably represent the most successful diagnostic strategy, combining existing diagnostics 
(SCr and urine output) and clinical risk scores with biomarkers-based diagnostics (the 
NephroCheck® Test) in relation to patient conditions. In particular, in a more heterogeneous 
patient context it might not be optimal to use biomarker testing routinely, but it could rather 
be more appropriate to identify a subset of patients in whom testing would be utilized more 
efficiently (Basu, Gist and Wheeler 2015). 
A crucial consideration concerns also the timing of the test. On the one hand, the 
primary purpose is to detect AKI as early as possible. On the other hand, if the test is 
performed too early, the biomarkers might have not increased enough to signal the risk of 
kidney injury. This trade-off must be solved analysing the responsiveness of biomarkers’ 
concentration to kidney damage, without forgetting that correct timing might be dependent on 
the population studied, besides the characteristics of the biomarker being analysed. 
 
The model constructed in this dissertation exploiting the results of the NephroCheck® 
Test actually allows early detection of AKI after cardiac surgery. Test assessment took place 
12h after surgery, which is much earlier than what current diagnostic methods allow (in the 
samples considered here, SCr usually does not increase until the third post-operative day). 
The scope for AKI prevention is, therefore, substantial even if it does not depend only on 
recognizing that a high risk of developing the injury exists, but also on the clinical measures 
that need to be started in order to prevent and treat the injury.  
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